Page 21234..1020..»

S-adenosylmethionine (SAM-e) Market Production, Revenue And Status forecast 2020 to 2026 – News Collective

The S-adenosylmethionine (SAM-e) Market an off-the-shelf research report for the year 2020-2026 has been recently added by Market Insights Reports to get an in-depth analysis of different attributes of industries and providing timely access to accurate, reliable and unbiased analysis of the market. The data provided related to the Market Size in value and volume*, top market segments driving sales and revenue, top companies, the share of the market in the market and the top countries which account for the maximum production and consumption.

The major manufacturers covered in this report:

Doctors Best, NutraLife, Jarrow Formulas, Now Foods, Life Extension, Source Naturals, California Gold Nutrition, Metabolic Maintenanc, and Others.

We aimed to provide most segmented consumption and sales data of different types of S-adenosylmethionine (SAM-e), downstream consumption fields and competitive landscape in different regions and countries around the world, this report analyzes the latest market data from the primary and secondary authoritative source.

Types Of Global S-adenosylmethionine (SAM-e) Market is Segmented as Follows:

Chemical Synthesis


Enzymatic Conversion

and others.

Sample PDF Copy of S-adenosylmethionine (SAM-e) Market 2019 :

Application Of Global S-adenosylmethionine (SAM-e) Market is Segmented as Follows:

Scientific Research

Clinical Treatment


and others.

We aim to deliver a high quality report with a relatively low cost thus delivering a optimum ROI and helping those involved in making informed, analytically driven decisions. Each of our reports has a database that has been researched and honed for the past 5 to 7 years, Along with this secondary sources referred to and studied include press releases, financial statements, analyst reports and other paid sources.

Special Offer: Avail Up to 20% Discount On S-adenosylmethionine (SAM-e) Report:

Geographical Regional Analysis :

The research mainly covers S-adenosylmethionine (SAM-e) market in

-North America (United States, Canada and Mexico)

-Europe industry (Germany, France, UK, Russia and Italy)

-Asia-Pacific (Southeast Asia, China, Korea, India and Japan)

-South America industry (Brazil, Argentina, Colombia)

-Middle East and Africa (Saudi Arabia, UAE, Egypt, Nigeria and South Africa)

Important Features that are under Offering and Key Highlights of the Reports:

-Detailed overview of S-adenosylmethionine (SAM-e) Market

-Changing market dynamics of the industry

-In-depth market segmentation by Type, Application etc.

-Historical, current and projected market size in terms of volume and value

-Recent industry trends and developments

-Competitive landscape of S-adenosylmethionine (SAM-e) Plant Market

-Strategies of key players and product offerings

-Potential and niche segments/regions exhibiting promising growth

This data is provided from 2014 to 2019 in actual and has been forecasted from 2020 to 2025 keeping in mind the current market trends, micro and macroeconomic factors and other legal and environmental factors affecting the market.

Buy complete S-adenosylmethionine (SAM-e) Market report at :

We also offer customization on reports based on specific client requirement:

1- Country level analysis for any 5 countries of your choice.

2- Competitive analysis of any 5 key market players.

3- 40 analyst hours to cover any other data points

Contact Us:

Irfan Tamboli (Head of Sales) Market Insights ReportPhone: + 1704 266 3234 | |

See original here:
S-adenosylmethionine (SAM-e) Market Production, Revenue And Status forecast 2020 to 2026 - News Collective

Recommendation and review posted by Bethany Smith

COVID-19 Impact on Global Male Breast Cancer Treatment Market Size, Status and Forecast 2020-2026,Top Key Players: Pfizer, Roche, GlaxoSmithKline,…

COVID-19 Impact on Global Male Breast Cancer Treatment Market Size, Status and Forecast 2020-2026, Key Regions, Types and Application, By Players, Type, Application, Marketing Channel and Region

This report focuses on the COVID-19 Impact on Global Male Breast Cancer Treatment Market status, future forecast, growth opportunity, key market and key players. The study objectives are to present COVID-19 Impact on Global Male Breast Cancer Treatment Market development in United States, Europe and China.

In 2019, COVID-19 Impact on Global Male Breast Cancer Treatment Market size was million US$ and it is expected to reach million US$ by the end of 2025, with a CAGR of during 2020-2025.

The report also summarizes the various types of COVID-19 Impact on Global Male Breast Cancer Treatment Market. Factors that influence the market growth of particular product category type and market status for it. A detailed study of COVID-19 Impact on Global Male Breast Cancer Treatment Market has been done to understand the various applications of the products usage and features. Readers looking for scope of growth with respect to product categories can get all the desired information over here, along with supporting figures and facts.

Get sample copy of this[emailprotected]

Top Key Players: Pfizer, Roche, GlaxoSmithKline, Sanofi, Novartis, Bayer, Bristol-Myers Squibb, Eli Lilly, AstraZeneca, Teva Pharmaceutical, Sun Pharmaceutical, BioNumerik Pharmaceuticals, Seattle Genetics, and Accord Healthcare

This report provides pinpoint analysis for changing competitive dynamics. It offers a forward-looking perspective on different factors driving or limiting market growth. It provides a five-year forecast assessed on the basis of how they COVID-19 Impact on Global Male Breast Cancer Treatment Market is predicted to grow. It helps in understanding the key product segments and their future and helps in making informed business decisions by having complete insights of market and by making in-depth analysis of market segments.

Key questions answered in the report include:

What will the market size and the growth rate be in 2026?

What are the key factors driving COVID-19 Impact on Global Male Breast Cancer Treatment Market?

What are the key market trends impacting the growth of COVID-19 Impact on Global Male Breast Cancer Treatment Market?

What are the challenges to market growth?

Who are the key vendors in COVID-19 Impact on Global Male Breast Cancer Treatment Market?

What are the market opportunities and threats faced by the vendors in COVID-19 Impact on Global Male Breast Cancer Treatment Market?

Trending factors influencing the market shares of the Americas, APAC, Europe, and MEA.

The report includes six parts, dealing with:

1.) Basic information;

2.) The Asia COVID-19 Impact on Global Male Breast Cancer Treatment Market;

3.) The North American COVID-19 Impact on Global Male Breast Cancer Treatment Market;

4.) The European COVID-19 Impact on Global Male Breast Cancer Treatment Market;

5.) Market entry and investment feasibility;

6.) The report conclusion.

All the research report is made by using two techniques that are Primary and secondary research. There are various dynamic features of the business, like client need and feedback from the customers. Before (company name) curate any report, it has studied in-depth from all dynamic aspects such as industrial structure, application, classification, and definition.

The report focuses on some very essential points and gives a piece of full information about Revenue, production, price, and market share.

COVID-19 Impact on Global Male Breast Cancer Treatment Market report will enlist all sections and research for each and every point without showing any indeterminate of the company.

Reasons for Buying this Report

This report provides pin-point analysis for changing competitive dynamics

It provides a forward looking perspective on different factors driving or restraining market growth

It provides a six-year forecast assessed on the basis of how the market is predicted to grow

It helps in understanding the key product segments and their future

It provides pin point analysis of changing competition dynamics and keeps you ahead of competitors

It helps in making informed business decisions by having complete insights of market and by making in-depth analysis of market segments


1 Report Overview

2 Global Growth Trends

3 Market Share by Key Players

4 Breakdown Data by Type and Application

5 United States

6 Europe

7 China

8 Japan

9 Southeast Asia

10 India

11 Central & South America

12 International Players Profiles

13 Market Forecast 2020-2026

14 Analysts Viewpoints/Conclusions

15 Appendix

Get Complete Brochure @

About Us:

Statistical surveying reports is a solitary goal for all the business, organization and nation reports. We highlight huge archive of most recent industry reports, driving and specialty organization profiles, and market measurements discharged by rumored private distributors and open associations. Statistical surveying Store is the far reaching gathering of market knowledge items and administrations accessible on air. We have statistical surveying reports from number of driving distributors and update our gathering day by day to furnish our customers with the moment online access to our database. With access to this database, our customers will have the option to profit by master bits of knowledge on worldwide businesses, items, and market patterns

Contact Us:

Lexis Business Insights


(Director- Business Development)

US: +1 210 907 4145

APAC: +91 9867799788


See the original post here:
COVID-19 Impact on Global Male Breast Cancer Treatment Market Size, Status and Forecast 2020-2026,Top Key Players: Pfizer, Roche, GlaxoSmithKline,...

Recommendation and review posted by Bethany Smith

Donating Stem Cells and Bone Marrow

People usually volunteer to donate stem cells for an allogeneic transplant either because they have a loved one or friend who needs a match or because they want to help people. Some people give their stem cells so they can get them back later if they need an autologous transplant.

People who want to donate stem cells or join a volunteer registry can speak with a health care provider or contact the National Marrow Donor Program to find the nearest donor center. Potential donors are asked questions to make sure they are healthy enough to donate and dont pose a risk of infection to the recipient. For more information about donor eligibility guidelines, contact Be the Match or the donor center in your area.

Be the Match (formerly the National Marrow Donor Program)Toll-free number: 1-800-MARROW-2 (1-800-627-7692)Website:

A simple blood test is done to learn the potential donors HLA type. There may be a one-time, tax-deductible fee of about $75 to $100 for this test. People who join a volunteer donor registry will most likely have their tissue type kept on file until they reach age 60.

Pregnant women who want to donate their babys cord blood should make arrangements for it early in the pregnancy, at least before the third trimester. Donation is safe, free, and does not affect the birth process.

If a possible stem cell donor is found to be a good match for a recipient, steps are taken to teach the donor about the transplant process and make sure he or she is making an informed decision. If a person decides to donate, a consent form must be signed after the risks of donating are fully discussed. The donor is not pressured to take part. Its always a choice.

If a person decides to donate, a medical exam and blood tests will be done to make sure the donor is in good health.

Stem cells may be collected from these 3 different sources:

Each method of collection is explained here.

This process is often called bone marrow harvest. Its done in an operating room, while the donor is under general anesthesia (given medicine to put them into a deep sleep so they dont feel pain). The marrow cells are taken from the back of the pelvic (hip) bone. The donor lies face down, and a large needle is put through the skin and into the back of the hip bone. Its pushed through the bone to the center and the thick, liquid marrow is pulled out through the needle. This is repeated several times until enough marrow has been taken out (harvested). The amount taken depends on the donors weight. Often, about 10% of the donors marrow, or about 2 pints, are collected. This takes about 1 to 2 hours. The body will replace these cells within 4 to 6 weeks. If blood was taken from the donor before the marrow donation, its often given back to the donor at this time.

After the bone marrow is harvested, the donor is taken to the recovery room while the anesthesia wears off. The donor may then be taken to a hospital room and watched until fully alert and able to eat and drink. In most cases, the donor is able to leave the hospital within a few hours or by the next morning.

The donor may have soreness, bruising, and aching at the back of the hips and lower back for a few days. Over-the-counter pain medications or nonsteroidal anti-inflammatory drugs are helpful. Some people may feel tired or weak, and have trouble walking for a few days. The donor might be told to take iron supplements until the number of red blood cells returns to normal. Most donors get back to their usual activities in 2 to 3 days. But it could take 2 or 3 weeks before they feel completely back to normal.

There arent many risks for donors and serious complications are rare. But bone marrow donation is a surgical procedure. Rare complications could include anesthesia reactions, infection, nerve or muscle damage, transfusion reactions (if a blood transfusion of someone elses blood is needed this doesnt happen if you get your own blood), or injury at the needle insertion sites. Problems such as sore throat or nausea may be caused by anesthesia.

Allogeneic stem cell donors do not have to pay for the harvesting because the recipients insurance company usually covers the cost. Even so, be sure to ask about insurance coverage before you decide to have the bone marrow harvest done.

Once the cells are collected, they are filtered through fine mesh screens. This prevents bone or fat particles from being given to the recipient. For an allogeneic or syngeneic transplant, the cells may be given to the recipient through a vein soon after they are harvested. Sometimes theyre frozen, for example, if the donor lives far away from the recipient.

For several days before starting the donation process, the donor is given a daily injection (shot) of a drug that causes the bone marrow to make and release a lot of stem cells into the blood. Filgrastim can cause some side effects, the most common being bone pain and headaches. These may be helped by over-the-counter pain medications or nonsteroidal anti-inflammatory drugs. Nausea, sleeping problems, low-grade (mild) fevers, and tiredness are other possible effects. These go away once the injections are finished and collection is completed.

After the shots, blood is removed through a catheter (a thin, flexible plastic tube) thats put in a large vein in the arm. Its then cycled through a machine that separates the stem cells from the other blood cells. The stem cells are kept while the rest of the blood is returned to the donor, often through the same catheter. (In some cases, a catheter may be put in each arm one takes out blood and the other puts it back.) This process is called apheresis. It takes about 2 to 4 hours and is done as an outpatient procedure. Often the process needs to be repeated daily for a few days, until enough stem cells have been collected.

Possible side effects of the catheter can include trouble placing the catheter in the vein, blockage of the catheter, or infection of the catheter or at the area where it enters the vein. Blood clots are another possible side effect. During the apheresis procedure, donors may have problems caused by low calcium levels from the anti-coagulant drug used to keep the blood from clotting in the machine. These can include feeling lightheaded or tingly, and having chills or muscle cramps. These go away after donation is complete, but may be treated by giving the donor calcium supplements.

The process of donating cells for yourself (autologous stem cell donation) is pretty much the same as when someone donates them for someone else (allogeneic donation). Its just that in autologous stem cell donation the donor is also the recipient, giving stem cells for his or her own use later on. For some people, there are a few differences. For instance, sometimes chemotherapy (chemo) is given before the growth factor drug is used to tell the body to make stem cells. Also, sometimes it can be hard to get enough stem cells from a person with cancer. Even after several days of apheresis, there may not be enough for the transplant. This is more likely to be a problem if the patient has had certain kinds of chemo in the past, or if they have an illness that affects their bone marrow.

Cord blood is the blood thats left in the placenta and umbilical cord after a baby is born. Collecting it does not pose any health risk to the infant or the mother. Cord blood transplants use blood that would otherwise be thrown away. After the umbilical cord is clamped and cut, the placenta and umbilical cord are cleaned. The cord blood is put into a sterile container, mixed with a preservative, and frozen until needed.

Some parents choose to donate their infants cord blood to a public blood bank, so that it may be used by anyone who needs it. Many hospitals collect cord blood for donation, which makes it easier for parents to donate. Parents can donate their newborns cord blood to volunteer or public cord blood banks at no cost. For more about donating your newborns cord blood, call 1-800-MARROW2 (1-800-627-7692) or visit Be the Match.

Other parents store their newborns cord blood in private cord blood banks just in case the child or a close relative needs it someday. If you want to donate or bank (save) your childs cord blood, youll need to arrange it before the baby is born. Some banks require you to set it up before the 28th week of pregnancy, although others accept later setups. Among other things, youll be asked to answer health questions and sign a consent form.

Parents may want to bank their childs cord blood if the family has a history of diseases that may benefit from stem cell transplant. There are several private companies offer this service. But here are some things to think about:

More information on private family cord blood banking can be found at the Parents Guide to Cord Blood Foundation. You can visit their website at

Continued here:
Donating Stem Cells and Bone Marrow

Recommendation and review posted by Bethany Smith

Bone Marrow Processing System Market Incisive Insights Regarding Major Regions, Key Players And Opportunities Up To 2025 – Kentucky Journal 24

Bone marrowaspiration and trephine biopsy are usually performed on the back of the hipbone, or posterior iliac crest. An aspirate can also be obtained from the sternum (breastbone). For the sternal aspirate, the patient lies on their back, with a pillow under the shoulder to raise the chest. A trephine biopsy should never be performed on the sternum, due to the risk of injury to blood vessels, lungs or the heart.

Get Access to sample pages @

The need to selectively isolate and concentrate selective cells, such as mononuclear cells, allogeneic cancer cells, T cells and others, is driving the market. Over 30,000 bone marrow transplants occur every year. The explosive growth of stem cells therapies represents the largest growth opportunity for bone marrow processing systems.Europe and North America spearheaded the market as of 2016, by contributing over 74.0% to the overall revenue. Majority of stem cell transplants are conducted in Europe, and it is one of the major factors contributing to the lucrative share in the cell harvesting system market.

In 2016, North America dominated the research landscape as more than 54.0% of stem cell clinical trials were conducted in this region. The region also accounts for the second largest number of stem cell transplantation, which is further driving the demand for harvesting in the region.Asia Pacific is anticipated to witness lucrative growth over the forecast period, owing to rising incidence of chronic diseases and increasing demand for stem cell transplantation along with stem cell-based therapy.

Japan and China are the biggest markets for harvesting systems in Asia Pacific. Emerging countries such as Mexico, South Korea, and South Africa are also expected to report lucrative growth over the forecast period. Growing investment by government bodies on stem cell-based research and increase in aging population can be attributed to the increasing demand for these therapies in these countries.

Major players operating in the global bone marrow processing systems market are ThermoGenesis (Cesca Therapeutics inc.), RegenMed Systems Inc., MK Alliance Inc., Fresenius Kabi AG, Harvest Technologies (Terumo BCT), Arthrex, Inc. and others

Covid 19 ImpactAnalysis@

Read this article:
Bone Marrow Processing System Market Incisive Insights Regarding Major Regions, Key Players And Opportunities Up To 2025 - Kentucky Journal 24

Recommendation and review posted by Bethany Smith

Stem Cell Therapy Market Analysis and Demand 2017 2025 – Cole of Duty

Global Stem Cell Therapy Market: Overview

Also called regenerative medicine, stem cell therapy encourages the reparative response of damaged, diseased, or dysfunctional tissue via the use of stem cells and their derivatives. Replacing the practice of organ transplantations, stem cell therapies have eliminated the dependence on availability of donors. Bone marrow transplant is perhaps the most commonly employed stem cell therapy.

Osteoarthritis, cerebral palsy, heart failure, multiple sclerosis and even hearing loss could be treated using stem cell therapies. Doctors have successfully performed stem cell transplants that significantly aid patients fight cancers such as leukemia and other blood-related diseases.

Know the Growth Opportunities in Emerging Markets

Global Stem Cell Therapy Market: Key Trends

The key factors influencing the growth of the global stem cell therapy market are increasing funds in the development of new stem lines, the advent of advanced genomic procedures used in stem cell analysis, and greater emphasis on human embryonic stem cells. As the traditional organ transplantations are associated with limitations such as infection, rejection, and immunosuppression along with high reliance on organ donors, the demand for stem cell therapy is likely to soar. The growing deployment of stem cells in the treatment of wounds and damaged skin, scarring, and grafts is another prominent catalyst of the market.

On the contrary, inadequate infrastructural facilities coupled with ethical issues related to embryonic stem cells might impede the growth of the market. However, the ongoing research for the manipulation of stem cells from cord blood cells, bone marrow, and skin for the treatment of ailments including cardiovascular and diabetes will open up new doors for the advancement of the market.

Global Stem Cell Therapy Market: Market Potential

A number of new studies, research projects, and development of novel therapies have come forth in the global market for stem cell therapy. Several of these treatments are in the pipeline, while many others have received approvals by regulatory bodies.

In March 2017, Belgian biotech company TiGenix announced that its cardiac stem cell therapy, AlloCSC-01 has successfully reached its phase I/II with positive results. Subsequently, it has been approved by the U.S. FDA. If this therapy is well- received by the market, nearly 1.9 million AMI patients could be treated through this stem cell therapy.

Another significant development is the granting of a patent to Israel-based Kadimastem Ltd. for its novel stem-cell based technology to be used in the treatment of multiple sclerosis (MS) and other similar conditions of the nervous system. The companys technology used for producing supporting cells in the central nervous system, taken from human stem cells such as myelin-producing cells is also covered in the patent.

The regional analysis covers:

Order this Report TOC for Detailed Statistics

Global Stem Cell Therapy Market: Regional Outlook

The global market for stem cell therapy can be segmented into Asia Pacific, North America, Latin America, Europe, and the Middle East and Africa. North America emerged as the leading regional market, triggered by the rising incidence of chronic health conditions and government support. Europe also displays significant growth potential, as the benefits of this therapy are increasingly acknowledged.

Asia Pacific is slated for maximum growth, thanks to the massive patient pool, bulk of investments in stem cell therapy projects, and the increasing recognition of growth opportunities in countries such as China, Japan, and India by the leading market players.

Global Stem Cell Therapy Market: Competitive Analysis

Several firms are adopting strategies such as mergers and acquisitions, collaborations, and partnerships, apart from product development with a view to attain a strong foothold in the global market for stem cell therapy.

Some of the major companies operating in the global market for stem cell therapy are RTI Surgical, Inc., MEDIPOST Co., Ltd., Osiris Therapeutics, Inc., NuVasive, Inc., Pharmicell Co., Ltd., Anterogen Co., Ltd., JCR Pharmaceuticals Co., Ltd., and Holostem Terapie Avanzate S.r.l.

Buy This Report @<ype=S

About TMR Research:

TMR Research is a premier provider of customized market research and consulting services to business entities keen on succeeding in todays supercharged economic climate. Armed with an experienced, dedicated, and dynamic team of analysts, we are redefining the way our clients conduct business by providing them with authoritative and trusted research studies in tune with the latest methodologies and market trends.

Continued here:
Stem Cell Therapy Market Analysis and Demand 2017 2025 - Cole of Duty

Recommendation and review posted by Bethany Smith

Mesenchymal Stem Cells Market trends by manufacturers, states, type and application, forecast to 2019 2027 – WhaTech Technology and Markets News

Mesenchymal Stem Cells Market Trends by Manufacturers, States, Type and Application, Forecast to 2019 2027

Global Mesenchymal Stem Cells Market: Snapshot

The increasing use of mesenchymal stem cells (MSCs) for the treatment of diseases and disabilities of the growing aging population is having a positive influence on the global mesenchymal stem cells market. Mesenchymal stem cells are adult stem cells that are of various types such as adipocytes, osteocytes, monocytes, and chondrocytes.

The main function of mesenchymal stem cells is to replace or repair damaged tissue.

Report Overview

Mesenchymal stem cells are multipotent, i.e. they can produce more than one type of specialized cells.

These specialized cells have their own distinguishing shapes, structures, and functions, with each of them belonging to a particular tissue.

Mesenchymal stem cells are traditionally found in the bone marrow. However, these cells can also be separated from other tissues such as cord blood, fallopian tube, peripheral blood, and fetal liver and lung.

Mesenchymal stem cells have long thin cell bodies containing a large nucleus. MSCs have enormous capacity for renewal keeping multipotency.

Due to these virtues, mesenchymal stem cells have huge therapeutic capacity for tissue repair.

Get Brochure of the Report

Mesenchymal stem cells can differentiate into a number of cell types that belong to our skeletal tissues that include cartilage, bone, and fat. Research is underway to discover if mesenchymal stem cells can be used to treat bone and cartilage diseases.

Scientists are also exploring the possibility if mesenchymal stem cells differentiate into other type of cells apart from skeletal tissues. This includes nerve cells, liver cells, heart muscle cells, and endothelial cells.

This will lead to mesenchymal stem cells to be used to treat other diseases.

Stem cells are specialized cells which have the capability of renewing themselves through cell division and differentiate into multi-lineage cells. Mesenchymal stem cells (MSCs) are non- hematopoietic, multipotent adult stem cells which can be isolated from bone marrow, cord blood, fat tissue, peripheral blood, fallopian tube, and fetal liver and lung tissue.

Request For Covid19 Impact Analysis

Mesenchymal stem cells have the capacity to differentiate into mesodermal lineages, such as chondrocytes, adipocytes, and osteocytes, and non-mesodermal lineages such as ectodermal (neurocytes) and endodermal lineages (hepatocytes). These stem cells have specific features such as multilineage potential, secretion of anti-inflammatory molecules, and immunomodulation.

These cells have emerged as promising therapeutic agents for regenerating skeletal tissues such as damaged bone and cartilage tissues and treatment of chronic diseases owing to their specific features.

The global mesenchymal stem cells market is expected to be driven by the increasing clinical application of mesenchymal stem cells for the treatment of chronic diseases, bone and cartilage diseases, and autoimmune diseases. Studies have shown that these stem cells enhance the angiogenesis in myocardium and allow the reduction of myocardial fibrotic area.

The pre-clinical studies for using mesenchymal stem cells in treatment of cardiovascular diseases, liver diseases, and cancer are projected to create new market opportunities for mesenchymal stem cells. Mesenchymal stem cells also produce anti-inflammatory molecules which modulate humoral and cellular immune responses.

Features of these stem cells such as ease of isolation, regenerative potential, and immunoregulatory, the mesenchymal stem cell therapy has emerged as a promising tool for the treatment of chronic diseases, degenerative, inflammatory, and autoimmune diseases.

Pre Book Now;ltype=S

Clinical studies are exploring MSCs for various conditions such as orthopedic injuries, graft versus host disease following bone marrow transplantation, and genetic modification of MSCs to overexpress antitumor genes for use as anticancer therapy, which are exhibiting new opportunities in therapeutic area. However, the mesenchymal stem cell research studies are tedious, lengthy, and complex.

In some cases, due to some adverse effects transplanted mesenchymal stem cells rapidly removed from the body which limits use of stem cells in therapeutic treatments. The conflicting results and regulatory compliances for approvals may also hamper the growth of this market.

The global mesenchymal stem cells market is segmented on the basis of source of isolation, end-user, and region. Stem cells are isolated from the bone marrow, peripheral blood, lung tissue, umbilical cord blood, amniotic fluids, adipose tissues, and synovial tissues.

Traditionally the MSCs were isolated from bone marrow aspiration which is associated with risk of infection and painful for the patient. The MSCs from adipose tissues are usually isolated from the biological material generated during liposuction, lipectomy procedures by using collagenase enzymatic digestion followed by centrifugation and washing.

In terms of end-user, the market is segmented into clinical research organizations, biotechnological companies, medical research institutes, and hospitals.

Read our Case study at

Geographically, the global mesenchymal stent cells market is distributed over North America, Europe, Asia Pacific, Latin America, and Middle East & Africa. North America dominated the global market and is projected to continue its dominance in terms of market share during the forecast period owing to high R&D expenditure, availability of advanced research facilities and skilled professionals, and government initiatives.

Europe is the second largest market after North America. The Asia Pacific market is projected to expand at a high CAGR during the forecast period due to increased R&D budgets in Japan, China, and India.

Key global players operating in the mesenchymal stem cells market include R&D Systems, Inc., Cell Applications, Inc., Axol Bioscience Ltd., Cyagen Biosciences Inc., Cytori Therapeutics Inc., Stemcelltechnologies Inc., BrainStorm Cell Therapeutics, Stemedica Cell Technologies, Inc., and Celprogen, Inc.

This email address is being protected from spambots. You need JavaScript enabled to view it.

See original here:
Mesenchymal Stem Cells Market trends by manufacturers, states, type and application, forecast to 2019 2027 - WhaTech Technology and Markets News

Recommendation and review posted by Bethany Smith

Longeveron Announces Japanese Approval of Clinical Trial for Treatment of Aging Frailty With Longeveron’s Stem Cells – Yahoo Finance

The Phase 2 study will assess the safety and efficacy of Longeveron's stem cell treatment under Japan's accelerated regulatory pathway for regenerative medicine.

MIAMI, June 1, 2020 /PRNewswire/ --Longeveron LLC announced today that Japan's Pharmaceutical and Medical Devices Agency (PMDA) (the Japanese agency akin to the United States' Food & Drug Administration) approved a Clinical Trial Notification (CTN) application (akin to an Investigational New Drug Application or "IND" in the US regulatory system), approving the initiation of a Phase 2 clinical trial evaluating the safety and efficacy of Longeveron's Mesenchymal Stem Cells (LMSCs) for the treatment of Aging Frailty in Japanese patients. This is another key milestone for Longeveron's Aging Frailty program, which includes two ongoing Phase 2 clinical trials in the U.S.

"We are extremely pleased to achieve this significant milestone," said Geoff Green, President of Longeveron."This study is designed to determine whether the transplant of donor-derived mesenchymal stem cells can improve healthspan in mild to moderately frail patients, thereby improving functionality and potentially lowering their risk of disability, and dependence on others for care."

Aging Frailty is a common, but reversible, life-threatening geriatric condition affecting millions of Japanese over the age of 65.Frail individuals are vulnerable to adverse health outcomes compared to their age-matched peers despite sharing similar comorbidities and demographics.Clinically, frailty manifests as a combination of symptoms that may include loss of muscle and decreased strength, slowed walking (sarcopenia), lower activity and energy levels, poor endurance, nutritional deficiencies, weight loss and fatigue.Collectively, these lead to overall decline in functionality, and increased risk of disability, dependency, and death.

"The biology of frailty is complex, and includes diminished stem cell activity, reduced ability to repair and regenerate tissue, and immunosenescence (deterioration of the immune system) and chronic systemic inflammation," said Dr. Anthony Oliva, Senior Scientist at Longeveron. "LMSCs have multiple mechanisms of action that can potentially address all of these issues, and thus make them extremely attractive as a therapeutic candidate for the unmet medical need of Aging Frailty."

The planned study is an investigator-initiated, randomized, double-blind, placebo-controlled design,and will be conducted at Juntendo University Hospital (Tokyo) and Japan's National Center for Geriatrics and Gerontology (NCGG) in Nagoya.The study's Principal Investigator, Dr. Hidenori Arai, President of the NCGG, commented that "Japan has one of the oldest and fastest aging societies in the world, with nearly 30% of Japan's citizens over the age of 65.Preventing and reversing functional decline associated with frailty is one of the nation's top priorities, and Longeveron's regenerative medicine approach is an exciting and innovative potential therapeutic option.With the disproportionate infection and mortality rate of older people with COVID-19 and Influenza infection, it is critically important to rapidly test treatments that may be effective."

In Japan, the "Pharmaceutical and Medical Device Act" and the "Act on the Safety of Regenerative Medicine" came into effect in 2014. Under this system, a "Time-limited Conditional Approval" option exists, which allows a manufacturer to conditionally sell regenerative medicine products while proceeding with its Phase 3 clinical trial.

Longeveron's Aging Frailty Research Program

Longeveron sponsors the most extensive and advanced Aging Frailty clinical research program in the world, with more than 200 patients treated with LMSCs worldwide.In the U.S., two clinical trials are currently ongoing:

About LMSCs

Longeveron Allogeneic Mesenchymal Stem Cells (LMSCs) is a regenerative medicine product sourced from the bone marrow of young healthy adult donors.LMSCs are culture expanded under the FDA's current good manufacturing practices (cGMP) to high standards, and maintained as individual "off-the-shelf" doses.

About Longeveron LLC

Longeveron ( is a regenerative medicine therapy company founded in 2014. Longeveron's mission is to provide biological solutions for aging-related diseases and life-threatening conditions, and is dedicated to developing safe and effective cell-based therapeutics for unmet medical needs such as Aging Frailty, the Metabolic Syndrome, Alzheimer's Disease, Acute Respiratory Distress Syndrome (ARDS) from COVID-19 infection, and congenital heart defects in children (hypoplastic left heart syndrome).

For information please contact:

Paul Lehr, JDplehr@longeveron.com305-338-6257

Related Images

longeveron.png LONGEVERON Longeveron - Biological Solutions for Aging

Related Links


View original content to download multimedia:


Read more from the original source:
Longeveron Announces Japanese Approval of Clinical Trial for Treatment of Aging Frailty With Longeveron's Stem Cells - Yahoo Finance

Recommendation and review posted by Bethany Smith

Study Demonstrating Role of IdeS in Enabling of Gene Therapy in the Presence of Neutralizing Anti-AAV Antibodies Published in Nature Medicine |…

DetailsCategory: Proteins and PeptidesPublished on Monday, 01 June 2020 18:40Hits: 389

PHILADELPHIA, PA, USA I June 01, 2020 I Spark Therapeutics, a fully integrated, commercial gene therapy company dedicated to challenging the inevitability of genetic disease, today announced the publication of new research in the journal Nature Medicine demonstrating that treatment with immunoglobulin G-degrading (IgG) enzyme of Streptococcus pyogenes (IdeS) resulted in rapid and transient reduction of neutralizing anti-adeno-associated virus (AAV) antibodies and restored gene therapy efficacy in controlled laboratory tests of animal models.

One of the main challenges associated with AAV-mediated gene therapy is neutralizing antibodies that can impact the ability to administer gene therapy, saidFederico Mingozzi, Ph.D., chief scientific officer atSpark Therapeutics. The IdeS technology has the potential to eliminate anti-AAV antibodies that allow for the extended use of gene therapy in a larger segment of candidates who may have been excluded due to pre-existing or developing neutralizing antibodies and also enable vector re-administration.

The study was conducted by an international collaboration of researchers from Spark Therapeutics in the U.S., and Genethon, the Centre de Recherche des Cordeliers (Inserm, Sorbonne Universit, Universit de Paris) and the National Centre for Scientific Research (CNRS) in France.

AAV-mediated gene therapy allows for the treatment of a growing number of diseases in patients today, however the presence of neutralizing anti-AAV antibodies can lead to limitations of this technology. Specifically, neutralizing anti-AAV IgG pre-exist in up to seventy percent of the population and block the entry of viral vector particles in a given target tissue. Furthermore, high-titer anti-AAV antibody levels usually develop following vector administration and persist long-term thereafter, preventing vector re-administration. To date, researchers have been limited in their ability to bypass the neutralizing activity of anti-AAV IgG.

Study FindingsThe study demonstrated that treatment with the IgG-degrading enzyme IdeS, an endopeptidase from Streptococcus pyogenes that specifically hydrolyses human IgG, resulted in a rapid and transient elimination of neutralizing anti-AAV IgG and restored gene therapy efficacy. IdeS is an endopeptidase able to degrade circulating IgG that is currently being tested in transplant patients.

Researchers demonstrated efficacy in vivo using animal models of liver gene transfer, including hemophilia A and B. Hemophilia is a rare genetic bleeding disorder that causes a delay in clot formation as a result of a deficiency in coagulation factor VIII or IX for hemophilia A or B, respectively. In both mice and non-human primates with neutralizing anti-AAV IgG, IdeS treatment prior to the injection of AAV vectors eliminated neutralizing IgG and rescued the expression of the factor VIII or IX in hepatocytes.

Furthermore, administration of AAV vectors systematically induces a neutralizing anti-AAV immune response, making gene therapy inefficient upon subsequent injections of AAV vectors. The study also demonstrated that treatment with IdeS restores the efficacy of the re-administration of AAV vectors, allowing for efficient transgene expression in non-human primates. The research shows that IdeS allows the repeated administration of AAV vectors by blocking the neutralizing activity of anti-AAV IgG in small and large animal models.

Additional studies in the field of gene therapy have the potential to translate these findings to human trials, with the goal of opening a therapeutic window for patients with neutralizing anti-AAV antibodies. Spark will assess and investigate the potential impact of the IdeS technology on its current gene therapy programs and potential applications in the future.

About Spark Therapeutics AtSpark Therapeutics, a fully integrated, commercial company committed to discovering, developing and delivering gene therapies, we challengethe inevitability of genetic diseases,includingblindness, hemophilia, lysosomal storage disorders and neurodegenerative diseases.We currently have four programs in clinical trials.At Spark, a member of the Roche Group, we see the path to a world where no life is limited by genetic disease. For more information, visit, and follow us on Twitter and LinkedIn.

SOURCE: Spark Therapeutics

See the article here:
Study Demonstrating Role of IdeS in Enabling of Gene Therapy in the Presence of Neutralizing Anti-AAV Antibodies Published in Nature Medicine |...

Recommendation and review posted by Bethany Smith

Tech Fort Worth client receives $2M research award from NEI – Fort Worth Business Press

Researchers at Bedford-based Nanoscope Technologies LLC have received a multi-year, $2-million plus Small Business Innovation ResearchAward from the National Eye Institute (NEI), a division of the National Institutes of Health (NIH), for its gene therapy treatment.

Nanoscopes research is advancing the development of a therapeutic gene and delivery platform for treating degenerative eye diseases, including dry age-related, macular degeneration (dry-AMD). The projected deliverable is a non-viral, spatially-targeted gene delivery platform for AMD therapy. It would restore visual response with targeted delivery of ambient-light, activatable opsin into the retina.

Our opto-genetic platform and laser delivery technologies are synergistic and will allow treatment for fully- and partially-degenerated retina, said Samarendra Mohanty, Ph.D., Principal Investigator of the grant and Chief Scientific Officer at Nanoscope.

This technology provides a unique therapeutic option for treating dry-AMD patients for which there is no approved therapy, said Vittorio Porciatti, Head of Research at the Bascom Palmer Eye Institute in south Florida.

The Nanoscope team developed Multi-Characteristic Opsins (MCOs) to sensitize cells toward low level of white light so that vision is improved at ambient room light. Not requiring any external stimulation device and sensitivity to broad range of colors makes our approach unique as there is less chance of phototoxicity and damage to the retina, said Nanoscope CEO Sulagna Bhattacharya.

Gene delivery by commonly used viral transfection may lead to unexpected inflammatory and immunological responses.To minimize collateral damage while inserting therapeutic genes, Nanoscopes process uses a low-power, near-infrared (NIR) laser beam whose intensity is locally enhanced by use of gold nanoparticles bound to the targeted cell membranes. This platform technology is being explored for delivery of genes for vaccination against diseases such as COVID-19.

Nanoscope is focused on advancing cell-gene therapy through various patented key platform technologies. Founded in 2009 by Mohanty, it has received multiple SBIR awards, National Institutes of Health R01 grants, and patents that focus on optical stimulation, gene delivery and imaging for neural activity monitoring.

See the rest here:
Tech Fort Worth client receives $2M research award from NEI - Fort Worth Business Press

Recommendation and review posted by Bethany Smith

Regeneron and Intellia Expand Their Hunt for Hemophilia A and B Treatments – BioSpace

Regeneron Pharmaceuticals and Intellia Therapeutics announced on Monday that they will be expanding an existing collaboration. Regeneron will have the rights to develop products for additional in viro CRISPR/Cas9-based therapeutic targets. In addition, both companies will work on creating products for the treatment of hemophilia A and B.

Regeneron will receive the non-exclusive rights to independently develop and commercialize ex vivo gene edited products, and Intellia will receive an upfront payment of $70 million. Regeneron will make an additional equity investment in Intellia of $30 million.

"The Regeneron team works hard to push the boundaries of science and technology, and we believe the precise in vivo gene insertion capabilities jointly developed with Intellia could be a promising therapeutic platform with significant potential in many diseases, including those that have been historically difficult to treat, said George D. Yancopoulos, M.D., Ph.D., Co-Founder, President and Chief Scientific Officer, Regeneron. We're pleased to expand our work with Intellia, a like-minded group of scientists focused on maximizing the potential of CRISPR/Cas9 in order to help as many patients as possible."

Both companies have made significant advances with Intellias CRISPR/Cas9 platform to perform the targeted insertion of therapeutic proteins and antibodies. In preclinical studies, Intellia and Regeneron demonstrated the first CRISPR/Cas9-mediated targeted transgene insertion in the liver of non-human primates. This generated normal or higher levels of circulating Factor IX, a blood-clotting protein that is missing or defective in hemophilia B patients.

"We're excited to work with Regeneron on what could potentially be a cure for hemophilia A and B in this expansion of our successful collaboration that builds on our leading insertion capabilities," said Intellia's Chief Executive Officer and President, John M. Leonard, M.D. "We believe that our CRISPR/Cas9-based technology addresses the limitations of current replacement and gene therapy approaches, and importantly, may provide a durable, potentially life-long solution to these genetic diseases."

Regeneron and Intellia arent the only companies looking for treatments for hemophilia. BioMarin Pharmaceutical, Inc. provided updates to the previously reported results from its open-label Phase 1/2 study on May 31. The trial looked into valoctocogene roxaparvovec as a form of treatment for adults with severe hemophilia A. People with this condition lack the necessary functioning Factor VIII proteins to help their blood clot.

All subjects in both the 6e13 vg/kg and 4e13 vg/kg cohorts remain off prophylactic Factor VIII treatment since being given a single dose of valoctocogene roxaparvovec. Cumulative mean annualized bleed rates remain less than one in both cohorts and below pre-treatment baseline levels.

Overall, the safety profile of valoctocogene roxaparvovec remains consistent with previously reported data, and no participants experienced thrombotic events. The U.S. Food and Drug Administration is currently reviewing the biologics license application from BioMarin.

"It's been a privilege to participate in this pioneering research and to observe how the patients on the study have done so much to improve our understanding of gene therapy research for hemophilia A. This additional data is an important step toward a potential first treatment of its kind for this devastating disease," said Professor John Pasi, M.B., Ch.B., Ph.D., from Barts and the London School of Medicine and Dentistry; chief investigator for the valoctocogene roxaparvovec Phase 1/2 study, and a principal investigator for the Phase 3 study. "Each year of data increases our knowledge of safety and efficacy and contributes to the growing body of scientific data on gene therapies in general and hemophilia A in particular."

Read the original here:
Regeneron and Intellia Expand Their Hunt for Hemophilia A and B Treatments - BioSpace

Recommendation and review posted by Bethany Smith

Toronto centre solving cell manufacturing challenges to benefit patients and global industry CCRM and Cytiva, formerly part of GE Healthcare Life…

TORONTO and MARLBOROUGH, Mass., June 02, 2020 (GLOBE NEWSWIRE) -- With Health Canada and the Food and Drug Administration beginning to approve and reimburse cell and gene therapies in significant numbers, the demand for cell and viral vector manufacturing will continue to grow. Consequently, the industrialization challenges associated with the variability of cell and gene therapies, and with manufacturing them on a commercial scale, must be overcome. CCRM and Cytiva, formerly part of GE Healthcare Life Sciences, have renewed their Collaboration Agreement for continued operation of the Centre for Advanced Therapeutic Cell Technologies (CATCT), which was created to accelerate the development and adoption of cell manufacturing technologies for novel regenerative medicine-based therapies.

Together, CCRM and Cytiva have established a commercialization hub where great minds, state-of-the-art equipment and a spirit of innovation meet, says Michael May, President and CEO of CCRM. Continuing to partner in the operation of CATCT will enable us to move the cell and gene therapy industry closer to fulfilling its promise of creating cures, and enabling treatments to get to patients.

By creating an innovative platform and approach to tackle the issues facing commercialization of living therapies, we are supporting the viability of the regenerative medicine industry, says Catarina Flyborg, Vice President, Cell & Gene Therapy, Cytiva. In CATCT, we are creating the technologies, processes and equipment that will enable our customers, and the broader industry, to achieve its goals and help patients.

Established in 2016, CATCT is a partnership between CCRM and Cytiva, with initial funding from the Federal Economic Development Agency for Southern Ontario (FedDev Ontario). Its staff of 40 works in a 10,000 ft (~930 m) process development facility, located in the MaRS Discovery District, next to Torontos world-leading hospitals and the University of Toronto.

The global regenerative medicine market was valued at US$23.8 billion (2018), and it is anticipated to grow to US$151 billion by 2026 with an annual growth rate of 26.1 per cent.i Operating CATCT allows CCRM and Cytiva to address the manufacturing bottlenecks that would otherwise have the potential to impede the industrys growth.

CATCTs key areas of expertise are:

The work conducted in CATCT can be categorized as follows: the first is fee-for-service development projects that advance customers therapeutic technologies towards industrialization; second, the teams New Product Introductions (NPIs) efforts provide core biological expertise in Cytivas product development process; finally, internal technology development builds additional capabilities and innovative solutions for cell and gene therapies.

A recent success stemming from the work being done in CATCT is the involvement of CCRM and Cytiva in a consortium led by iVexSol Canada, with conditional funding from Next Generation Manufacturing Canada (NGen), to build an advanced manufacturing platform for lentiviral vectors. As core partners in this consortium, which was announced in August 2019, CCRM will provide supporting manufacturing infrastructure and downstream processing capabilities, and Cytiva will share expertise of manufacturing processes, and access to and use of specialized tools and technology.

The new collaboration agreement between CCRM and Cytiva has a three-year term and it became effective on October 15, 2019. The funding will be a combination of in-kind contributions, milestone payments, reinvested fee-for-service revenue and any successful grant opportunities. FedDevs funding of CATCT was for a three-year term and ended in December 2018.

About CCRM CCRM, a Canadian not-for-profit organization funded by the Government of Canada, the Province of Ontario, and leading academic and industry partners, supports the development of regenerative medicines and associated enabling technologies, with a specific focus on cell and gene therapy. A network of researchers, leading companies, strategic investors and entrepreneurs, CCRM accelerates the translation of scientific discovery into new companies and marketable products for patients, with specialized teams, funding, and infrastructure. CCRM is the commercialization partner of the Ontario Institute for Regenerative Medicine and the University of Torontos Medicine by Design. CCRM is hosted by the University of Toronto. Visit us at

About CytivaCytiva is a 3.3 billion USD global life sciences leader with nearly 7,000 associates operating in 40 countries dedicated to advancing and accelerating therapeutics. As a trusted partner to customers that range in scale and scope, Cytiva brings speed, efficiency and capacity to research and manufacturing workflows, enabling the development, manufacture and delivery of transformative medicines to patients. Visit for more.

For more information, please contact:

Stacey JohnsonDirector, Communications and Marketing,

Colleen ConnollySenior Communications Manager,


Toronto centre solving cell manufacturing challenges to benefit patients and global industry CCRM and Cytiva, formerly part of GE Healthcare Life...

Recommendation and review posted by Bethany Smith

growth factors to cut cell therapy COGS – Bioprocess Insider – BioProcess Insider

Cell therapy manufacturing costs could be reduced dramatically using immobilized growth factors in culture according to research.

Industry interest in cell therapies has increased significantly in recent years. According to a report by US industry group PhRMA, there are 362 cell and gene therapies in clinical development, up from 289 in 2018.

The surge in cell therapies entering the clinic is the result of years of pioneering research by Americas biopharmaceutical research companies, according to PhRMA.

Image: iStock/Sviatlana Zyhmantovich

It also reflects the potential revenue cell therapies can generate. According to analysis by market research firm Bioinformant while prices vary, all cell therapies are expensive.

For example, cell therapies for wound care cost between $1,500 and $2,500 per administration, while those delivered via injection can cost up to $200,000 per shot. Cell-based gene therapies are valued in the $500,000 to $1 million range.

But revenue is not the only factor. The prices also reflect the high cost of goods sold (COGS) for a cell therapy according to Bioinformant.

The cost of manufacturing a cell product cannot be compared with small molecule products manufactured by pharmaceutical companies or biomolecules produced by biotechnology companies. Cell therapies are costlier to develop, with autologous cell products commanding the highest price tags.

In general, the manufacturing cost of autologous cell product is many times higher than that of an allogeneic product and this is reflected in the market pricing the authors wrote.

Growth factors as the name suggests are proteins that stimulate cell growth. They are one of the most costly components of the cell therapy manufacturing process according to a 2018 study published in Frontiers in Medicine.

The authors who looked at production strategies for allogenic therapies said Identifying mimetic-based alternatives to costly growth factors or leaner media alternatives would help to substantially reduce cost of goods.

Another approach is to immobilize growth factors used in cell culture according to the team behind a study due to be published in Frontiers in Bioengineering and Biotechnology.

Author Marion Brunck, associate professor at the Monterrey Institute of Technology and Higher Education (ITESM), told Bioprocess Insider Immobilizing growth factors is a good idea in general, as the process stabilizes the protein and prevents its degradation, internalization, i.e. bioactivity does not decrease at the same rate as with soluble proteins.

However, some growth factors must be internalized for the transduction cascade to occur appropriately, in these situations, a different approach may be sought out, for example immobilizing the growth factor by physical entrapment which allow a gradual release in culture media.

The take home message is that it may be a very good idea to decrease production cost but the biology of the growth factor (GF) and its signaling mechanistics must be well known.

Brunck added that, The impact of GF immobilization on cost will definitely vary depending on each individual process. In some cases, culture media accounts for more than half of the cost of goods, and within the cost of culture media, GF is again a big contributor.

View original post here:
growth factors to cut cell therapy COGS - Bioprocess Insider - BioProcess Insider

Recommendation and review posted by Bethany Smith

Rise and Opportunities in Gene Therapy Market, Poised to Register Downturn due to COVID-19 Pandemic – The Cloud Tribune

A business intelligence report on the global Gene Therapy market offers quantitative estimation of the opportunities and qualitative assessment various growth dynamics. The study highlights estimations of the opportunities in the historical period, and offers several projections during the forecast period.

The following are taken into consideration:

Request to View Sample of Research Report @

Key Focus Areas of Report on Global Gene Therapy Market

The study on the Gene Therapy market includes detailed market estimations of opportunities in various segments and their share/size globally in each year during the forecast period. The following are the broad insights that form the backbone of the evaluation of the Gene Therapy market.

Segmental Analysis Comprise the following.

Based on End-use Industry/Application,

Based on Product/Technology,

Based on Region,

Top players include

What Businesses Can Hope to Get in Business Intelligence on Gene Therapy Market?

The study insights on the Gene Therapy market growth dynamics and opportunities highlights various key aspects, in which crucial ones are:

To Know More Information about This Report, Ask The Analyst @

Insights and Perspectives that make this Study on Gene Therapy Market Stand Out

The analysts who have prepared the report have been keen observers of the dynamism due to macroeconomic upheavals. Using the best industry assessment quantitative methods and data integration technologies, they have come out with a holistic overview of the future growth trajectories of the Gene Therapy market. Fact-based insights and easy-to-comprehend information based on wide spectrum of market data is what makes this study different from competitors.

The following evaluations create a differentiating approach towards understanding the market dynamics and presenting the crux to its readers:

About Fact.MR

Fact.MR is a fast-growing market research firm that offers the most comprehensive suite of syndicated and customized market research reports. We believe transformative intelligence can educate and inspire businesses to make smarter decisions. We know the limitations of the one-size-fits-all approach; thats why we publish multi-industry global, regional, and country-specific research reports.

Contact Us


11140 Rockville Pike

Suite 400

Rockville, MD 20852

United States


Media Release:

Read the rest here:
Rise and Opportunities in Gene Therapy Market, Poised to Register Downturn due to COVID-19 Pandemic - The Cloud Tribune

Recommendation and review posted by Bethany Smith

Cell And Gene Therapy Consumables Market to Witness Huge Growth by 2027 | Amgen Inc., ATLANTA BIOLOGICALS, bluebird bio, Inc., Cook Medical, Dendreon…

Global Cell And Gene Therapy Consumables market report comprises of detailed explanation of the market definition, classifications, applications, commitments and market trends. The above-mentioned report provides the levels and revenue of the CAGR for the historical year 2016, the base year 2017 and the forecast period for the Cell And Gene Therapy Consumables market between 2020 and 2027. Getting data regarding competitive landscape is a great gain of this market document. Consequently, the actions or actions of most important market game enthusiasts and brands are analyzed within the Cell And Gene Therapy Consumables Research Report. It provides data on all recent developments, launches of products, joint ventures, mergers and acquisitions by the various key market dominant players and brands. These key players company profiles are provided in this report. In the 2020-2027 forecast period, the market will touch new heights. This Cell And Gene Therapy Consumables report lays down all the restrictions and drivers for the market derived from SWOT analysis.

Negative consequences of internet of things could act as a market restraint for Cell And Gene Therapy Consumables in the above mentioned foretasted period.

Request for a Sample [emailprotected]

Key market [emailprotected]

The report provides both qualitative and quantitative research of cell and gene therapy consumables market as well as provides comprehensive insights and development methods adopted by the prominent market players. Some of the key market participants in the cell and gene therapy consumables market are Amgen Inc., ATLANTA BIOLOGICALS, bluebird bio, Inc., Cook Medical, Dendreon Pharmaceuticals LLC, Fibrocell Science, Inc., General Electric, Kolon TissueGene, Inc., Orchard Therapeutics plc, Pfizer, Inc., PromoCell GmbH, RENOVA THERAPEUTICS, Sibiono GeneTech Co. Ltd., Spark Therapeutics, Inc., Vericel, ViroMed Co., Ltd., and Vitrolife. These players have adopted growth strategies such as new product launches, partnerships, collaborations, mergers and acquisitions, and joint ventures (JVs) in order to gain a competitive advantage. For instance, in May 2019, General Electric launched chronicle automation software for cell therapy. In October 2018, bluebird bio, Inc. received an approval from European Medicines Agency (EMA) for its investigational LentiGlobin gene therapy for the treatment of adolescents and adults with transfusion-dependent -thalassemia (TDT).

Key Market Competitors: Global Cell And Gene Therapy Consumables Market

Cell And Gene Therapy Consumables Market Country Level Analysis

Cell And Gene Therapy Consumables market is analysed and market size, volume information is provided by country, product type, cable category, application and end use as referenced above.

The countries covered in the Cell And Gene Therapy Consumables market report are the U.S., Canada and Mexico in North America, Brazil, Argentina and Rest of South America as part of South America, Germany, Italy, U.K., France, Spain, Netherlands, Belgium, Switzerland, Turkey, Russia, Rest of Europe in Europe, Japan, China, India, South Korea, Australia, Singapore, Malaysia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA).

Enquiry Before @

Rapid Business Growth Factors

In addition, the market is growing at a fast pace and the report shows us that there are a couple of key factors behind that. The most important factor thats helping the market grow faster than usual is the tough competition.

Competitive Landscape and Cell And Gene Therapy Consumables Market Share Analysis

Cell And Gene Therapy Consumables market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, regional presence, company strengths and weaknesses, product launch, product width and breadth, application dominance. The above data points provided are only related to the companies focus related to Cell And Gene Therapy Consumables market.

Request for [emailprotected]

Table Of Contents: Global Cell And Gene Therapy Consumables Market

Part 01: Executive Summary

Part 02: Scope Of The Report

Part 03: Research Methodology

Part 04: Market Landscape

Part 05: Pipeline Analysis

Part 06: Market Sizing

Part 07: Five Forces Analysis

Part 08: Market Segmentation

Part 09: Customer Landscape

Part 10: Regional Landscape

Part 11: Decision Framework

Part 12: Drivers And Challenges

Part 13: Market Trends

Part 14: Vendor Landscape

Part 15: Vendor Analysis

Part 16: Appendix

More here:
Cell And Gene Therapy Consumables Market to Witness Huge Growth by 2027 | Amgen Inc., ATLANTA BIOLOGICALS, bluebird bio, Inc., Cook Medical, Dendreon...

Recommendation and review posted by Bethany Smith

Shinshu University and Toshiba Develop Tumor-Tropic Liposome Technology that Carries Therapeutic Genes into Cancer Cells – BioSpace

TOKYOToshiba Corporation (TOKYO: 6502, hereinafter Toshiba) and a team led by Professor Yozo Nakazawa at the Department of Pediatrics, Shinshu University, (hereinafter "Shinshu University"), have together developed a tumor-tropic liposome technology for gene therapy*1. The technology uses unique, nano-sized biodegradable liposomes developed by Toshiba to accurately and efficiently deliver therapeutic genes to targeted cancer cells, and achieves safer gene delivery than viruses used as carriers.

The tumor-tropic liposome developed by Toshiba can deliver therapeutic genes selectively to tumor cells, not normal cells. Shinshu university and Toshiba have demonstrated that the tumor-tropic liposome can deliver the therapeutic gene to T-cell leukemia cells and achieve a 30-fold increase in uptake and 400-fold increase in gene expressionthan normal T-cells. The technology is expected to reduce burdens on patients during treatment, and offers the potential to develop new treatments for other cancers.

Shinshu University and Toshiba presented the technology at the 2020 Annual Meeting of the American Society for Gene & Cell Therapy (ASGCT 2020) on May 12 (presenter: Shoji Saito, Shinshu University School of Medicine).

Gene therapy applies the latest advances in biotechnology to treatment of disease at the level of gene expressionusing information from a gene to synthesize a functional gene product in an affected cell. In cancer therapy, it inserts therapeutic genes into target cells, where they can repair and enhance cell functions. While a highly promising way forward, even for cancers that are difficult to treat, gene therapy is not yet settled science, and there are still hurdles to overcome, including how best to get genes into cells.

Therapeutic genes need a carrier to introduce them into a cell, because the nucleic acid that encodes the DNA and RNA that triggers gene expression cannot penetrate the cell membrane. Current approaches often achieve this by using a virus as the carrier. However, it brings with concerns for the risk of infection and cell tropism.

Shinshu University and Toshiba are collaborating in research to utilize biodegradable liposomes as non-virus carriers of therapeutic genes. They have developed tumor-tropic liposomes that safely and effectively deliver therapeutic genes to targeted cancer cells.

Toshiba has applied its know-how in materials technology to the design of liposomes with lipids that degrade naturally in cells, as their major component. The companys research has confirmed that adjusting lipid composition to cell membrane characteristics realizes liposomes that can carry therapeutic genes to specific target cells (Figure 1). The delivery is also highly efficient, as a comparison of tumorous cells and normal T cells found that the former surpassed the latter in therapeutic gene uptake and expression by 30-times and 400 times respectively.

Figure 1 The biodegradable liposome technology targeted by the research

Shinshu University has demonstrated that the biodegradable liposome is an effective and efficient carrier for delivering therapeutic genes into tumor cells by experimentally administering tumor-tropic liposomes carrying therapeutic genes into T-cell tumor bearing mice. The results also confirmed successful suppression of tumor growth (Figure 2). As there is no effective treatment for relapsed or refractory T-cell tumors, Shinshu University is continuing research toward a solution.

Figure 2 Verification of the effects of tumor-tropic liposomes on mice bearing T-cell tumors

Toshiba will continue to contribute its specialized capabilities in materials science to the collaboration with Shinshu University, in support of further enhancing the delivery and application of cancer-directed liposomes and promoting the widespread use of gene therapy.

*1 Gene Therapy

A method of treating a disease by inserting a gene into a cell in order to restore, enhance or suppress its function. It is based on the physiological action of a protein produced by the gene.

Originally posted here:
Shinshu University and Toshiba Develop Tumor-Tropic Liposome Technology that Carries Therapeutic Genes into Cancer Cells - BioSpace

Recommendation and review posted by Bethany Smith

Gene Therapy Market 2020 | Worldwide Analysis By Financial Overview, Research Methodologies and Forecast To 2028 – Azizsalon News

In its forthcoming study ofGlobalGene therapy Market,Quince Market Insights offers crucial insights into the global market forGene therapy. In terms of revenue, the global market forGene therapyis expected to record a CAGR ofXXpercent over the forecast period, due to various factors with regard to which QMI provides detailed insights and forecasts.

Click here to get sample of the premium report

The demand forGene therapyis projected to report a growth rate ofXXper cent year-over-year by2028. The demand forGene therapyis segmented by product type, end-users, and regions.

During consideration of segments and sub-segments some industry standards and parameters are considered. Historical information on theGene therapymarket as well as future occurrences which could impact market growth includes a microscopic market view. In view of the value for the base year, the market volume or demand is determined. Main regions are kept in mind with special emphasis on the highest demand and growth countries. The report details country-specific economic indicators and drivers with the investment opportunities offered to the investors concerned. Key insights are written into a table and easily readable structured.

The growth of the market forGene therapyis related to the dental industry that would benefit a great deal from the ongoing change in production using digital methods. As the technology continues to advance traditional methods, further improvements in treatments and outcomes resulting from digital manipulation are improved.Products are more furiously embraced in emerging markets because they are cost-effective and offer good quality that fits the present condition and certain points ofGene therapyrefund policies.

Gene therapymarket research report provides an in-depth analysis of the market overall, primarily on issues bordering on the market size, growth scenario, opportunity potentials, business environment, trend analysis and competitive market analysis ofGene therapy. The information includes the profile of the company, annual turnover, the types of products and services it provides, income generation, which gives businesses direction to take important steps.Gene therapyresearch reportprovides pin-point analysis of varying dynamics of competition and is ahead of competitors in theGene therapylike:Alliance for Regenerative Medicine, Gilead Sciences, Inc., Novartis AG, Sibiono GeneTech Co. Ltd.

This report analyses the trends that drive the growth of each segment on a global as well as regional level, and provides potential takeaways that could prove significantly useful for manufacturers preparing to enter the market.

In this article, we addressed the specific approaches these businesses have adopted with regard to developing their products, creating new manufacturing facilities, consolidating the market and advanced R&D initiatives. The study ends with key takeaways for players already present on the market and new players preparing to enter the marketGene therapy.

Get Scope of the actual premium report

Market Segmentation:

By Product: Yescarta Kymriah Luxturna Strimvelis GendicineBy Application: Ophthalmology Oncology Adenosine Deaminase Deficient Severe Combined ImmunodeficiencyBy Region: North America North America, by CountryUSCanadaMexico North America, by Product North America, by Application Western Europe Western Europe, by CountryGermanyUKFranceItalySpainThe NetherlandsRest of Western Europe Western Europe, by Product Western Europe, by Application Asia Pacific Asia Pacific, by CountryChinaIndiaJapanSouth KoreaAustraliaIndonesiaRest of Asia Pacific Asia Pacific, by Product Asia Pacific, by Application Eastern Europe Eastern Europe, by CountryRussiaTurkeyRest of Eastern Europe Eastern Europe, by Product Eastern Europe, by Application Middle East Middle East, by CountryUAESaudi ArabiaQatarIranRest of Middle East Middle East, by Product Middle East, by Application Rest of the World Rest of the World, by CountrySouth AmericaAfrica Rest of the World, by Product Rest of the World, by Application


QMI has the most comprehensive collection of market research products and services available on the web. We deliver reports from virtually all major publications and refresh our list regularly to provide you with immediate online access to the worlds most extensive and up-to-date archive of professional insights into global markets, companies, goods, and patterns.

Contact Us

Quince Market InsightsAjay D. (Knowledge Partner)Office No- A109,Pune, Maharashtra 411028Phone: +91 706 672 5858/+1 208 405 2835/+91 706 672

See the article here:
Gene Therapy Market 2020 | Worldwide Analysis By Financial Overview, Research Methodologies and Forecast To 2028 - Azizsalon News

Recommendation and review posted by Bethany Smith

Cell and gene therapies – Lexology

In recent years, we have seen a trend towards the launch of new gene and cell therapies with record-breaking price tags. Such headline-grabbing launches are becoming more and more frequent, as the pipeline for advanced therapies at all stages of development continues to grow at a rapid pace[1]. We are also seeing industry and payers adopting new innovative pricing models for those products, such as outcome-based reimbursement and annuity payment models. In this article, we discuss these emerging alternative pricing models and consider the impact they may have on related licensing arrangements.

Current trends

In May 2019 AveXis, a subsidiary of pharmaceutical giant Novartis, announced that it had received approval from the US Food and Drug Administration to market its gene therapy Zolgensma for the treatment of paediatric patients with spinal muscular atrophy (SMA). Although this is the first promise of a cure for this debilitating and lethal condition, the media coverage focussed instead on Zolgensmas price tag, which at $2.1 million per patient makes it (currently) the worlds most expensive single-dose medicine.

Zolgensma is illustrative of a general trend in gene and cell therapies that have reached the market in recent years and established a new standard of pricing for single-treatment medicines. While manufacturers point to the relative cost-effectiveness of such treatments (which may offer a one-off cure for severe conditions that otherwise would require several years worth of conventional treatments and care) public and private payers are concerned about this new escalating pricing paradigm.

Health care systems may be able to absorb such high prices for rare diseases with small patient populations. However, the current reimbursement systems will be under severe pressure if (as is hoped) pipelines for advanced cell and gene therapies result in treatments for common conditions such as diabetes or heart disease. The Institute for Clinical and Economic Review in the US has estimated that if gene therapies are developed to treat only one in ten American patients with a genetic condition approximately 1% of the total population the cumulative budget impact could rise to $3 trillion[2]. For comparison, the projected total healthcare spend in the US for 2019 is $3.8 trillion[3].

Alternative Pricing Models

The pharmaceutical industry has sought to counter criticism over the high price tags for gene and cell therapies by coupling these revolutionary therapies with new and unconventional pricing and reimbursement mechanisms.

One alternative structure that has been adopted is an annuity based model which spreads the payment for an expensive treatment over several years in a pre-agreed payment plan, thus minimising the up-front cost to payers.

Another approach adopted by the industry, and perhaps an even clearer way to demonstrate value to payers, has been to tie reimbursement to patient outcomes. The industry has negotiated several of these outcomes-based reimbursement models with public and private payers for cell and gene therapies. Reimbursement payments to the drug maker under this model are conditional upon the patient reaching specific clinical outcomes by set deadlines. Depending on the model, a patients failure to meet the specified clinical outcome can result in the drug maker having to refund payments received and/or forfeit any subsequent payments.

These new models are also being blended to create payment plans which combine annuity-style payments with rebates and outcomes-dependent instalments. We expect that in the years to come other creative payment models will emerge and be adapted from other therapy areas. For example, in Australia, the government has used a subscription style model that allowed it to pay a lump sum to drug makers for unlimited access for patients to curative hepatitis C treatments such as Sovaldi for a period of time.

Example annuity and outcomes-based reimbursement models for cell and gene therapies:

Licensing challenges

Cell and gene therapies often have their roots in academic research laboratories and the main players in this field of treatments have close ties and valuable licensing agreements with academic research institutions. For example, AveXis, the biotech company that developed Zolgensma, started as a spin-out to continue research conducted at the Center for Gene Therapy at Nationwide Childrens Hospital in Columbus, Ohio. To further its spinal muscular atrophy work, the biotech also licensed a patent owned by Martine Barkats, a researcher at the Institut de Myologie, Paris. Shortly after, AveXis was bought by Novartis for $8.7 billion. Cell and gene therapies such as Zolgensma will generally have more constituent parts (such as promoters, viral vectors and cell lines) than other more conventional small molecule therapies. This means that a party commercialising a cell or gene therapy will often need to license in more third party intellectual property or materials than a manufacturer of a conventional small molecule therapy. Most cell and gene therapies reaching the market are therefore likely to be underpinned by one or more licence agreements.Licensing challenges

While much has been said about the impact of alternative pricing and reimbursement mechanisms on drug makers, payers and patients, we want to also consider the impact on licensors of the intellectual property which enables the development and manufacture of a therapy. In particular, how future pricing and reimbursement models can impact the royalties payable by licensees to their licensors. One inherent challenge is that these licences are generally negotiated many years before the commencement of discussions with payers on pricing and reimbursement mechanisms, making it very difficult to predict which scenarios will be relevant down the line. The positions of all of the stakeholders in the pricing debate are also constantly evolving, especially as data on the cost-effectiveness of annuity and outcomes-based models continues to accumulate. One factor which makes things particularly difficult for licensors in forecasting potential future royalty streams for these products is that a licensor would rarely have any involvement in negotiations regarding pricing and reimbursement so will have no control over the model adopted.

Annuity model challenges

Generally a licensor will only receive royalties once the licensee has itself received (or at least invoiced) payment from payers. An annuity payment model is therefore likely to mean that royalties will also be paid in instalments potentially spread over a number of years following treatment of a patient. While in practice this may not be a large change for licensors to adjust to (as annual payments for these high price treatments are not out of line with other orphan drug costs, most of which need to be taken over a long period of time) there are also other factors to consider.

One concern that has been raised with annuity payment models is that there may be an increased risk of non-payment as over time licensees may face difficulties in collecting payments, for example because a payer stops complying with payment schedules or becomes insolvent. This may have the knock-on effect of reducing royalties due to a licensor. Licensors may seek to reduce this non-payment risk by asking that royalties are payable on sums invoiced by a licensee, rather than sums received (although this is likely to be resisted by a licensee or perhaps only accepted with caveats). Annuity-based models are also typically more complicated and more expensive for a licensee to manage administratively and those costs are likely to be deductible from sales totals before a licensors royalties are calculated.

From a legal drafting perspective, care would also need to be taken by the licensor when defining payment terms and the royalty term (which is commonly linked to patent expiry) to ensure that the licensor continued to receive royalties in respect of patients who are treated within the royalty term, notwithstanding the fact that payment may not be received until after the patents and royalty term has expired.

Outcome-based model challenges

In relation to outcome-based models, a fundamental concern for both licensors and licensees is the uncertainty associated with a model which involves an upfront payment of the full treatment price but a refund payable some months or years down the line if the clinical outcomes are not met.

If royalties are payable on net sales of the therapy on a regular basis (e.g. quarterly or annually) then unless the licence includes a mechanism to take account of outcomes-based refunds made by the licensee to payers, the licensee could find itself out of pocket, unable to recover royalties paid to the licensor despite having had to refund the therapy price to the payer. To counter this risk, a licensee may seek to build in a royalty claw back mechanism into the licence, or to delay the point at which royalties are payable until after the relevant patient has met the required outcome. However, a licensor is unlikely to accept a significant delay in payment of royalties, particularly where the licensee has itself been paid. Academic licensors, with an obligation to invest income from technology transfer activities into research and the provision of education, are particularly unlikely to agree a royalty claw back structure which could force them to refund royalties or milestones a year or more after having received them.

One alternative option may be to agree that the licensee can make deductions against future royalty payments. A further alternative could be for some portion of the royalties paid to be retained in escrow for a period of time, to be released to the licensor upon achievement of a positive clinical outcome or expiry of a set period of time. However, escrow arrangements necessarily increase the complexity of agreements and are difficult to negotiate upfront when payment and reimbursement models and the associated outcome triggers have not yet been set.

A compromise?

As we have outlined in this article, although there are some things each party can consider at the outset of negotiating a licence, getting into protracted negotiations about hypothetical scenarios is unlikely to be attractive to either party.

The parties may wish to adopt an alternative approach of including robust governance provisions in the licence to deal specifically with this issue. For example, establishing a committee comprised of representatives of both parties to oversee and review issues relating to pricing and reimbursement. This may give the licensor a clearer oversight (and potentially input) into decisions which may impact future royalty streams and may present the licensee with an opportunity to propose alternative payment structures to support its desired pricing model. This could be combined with a mechanism for proposing and agreeing amendments to payment provisions in the licence if necessary to accommodate pricing and reimbursement issues which were unforeseen at the outset. Of course the success of such mechanisms will depend on the strength of the relationship between the parties and a combined willingness to work together and potentially compromise. It would also be important to ensure it is clear what happens where the parties cannot agree (e.g. escalation? expert determination? preservation of the status quo?). However, in a future where pricing and reimbursement issues are only likely to become more complex and of key importance to the success of complex treatments such as cell and gene therapies, it will be interesting to see whether this is a route industry explores.


The launch in recent years of a number of advanced cell and gene therapies with blockbuster price tags has heralded a new era for drug pricing and associated payment and reimbursement issues. It is a trend that looks likely to continue if current pipelines can also deliver much anticipated advanced therapies for common conditions. The high prices associated with these products present a myriad of issues however, not only for patients, payers and healthcare providers, but also for the licensors of the underlying intellectual property underpinning such treatments as industry adopts innovative new payment and reimbursement models which may impact on royalty streams.

When negotiating a licence to technology underpinning a cell or gene therapy the parties should consider how less conventional pricing mechanisms may impact the royalty structure. However, while there are some issues licensees and licensors may be able to consider upfront, it is difficult to anticipate the issues that may become relevant at a stage where pricing models have not been set, particularly as there is no one-size-fits-all pricing approach.

We have proposed an increased use of robust governance processes in a licensing relationship as one option to consider. It will also be interesting to see whether any trends emerge in relation to upfront and milestone payments in response to the challenges outlined above. In particular, licensees may push for more back-loaded or performance-related milestone payments to reflect the risks associated with pricing models which take a longer term view of the cost benefits of these types of therapies. We look forward to seeing what innovative approaches licensors and licensees adopt to adapt to these challenges in the years to come.

See original here:
Cell and gene therapies - Lexology

Recommendation and review posted by Bethany Smith

Diabetic Peripheral Neuropathy Market is Expected to Increase with a CAGR of 12% for the Study Period of 2017-2030: DelveInsight – P&T Community

LAS VEGAS, June 2, 2020 /PRNewswire/ -- Diabetic Peripheral Neuropathy Market will increase because of the rising global burden of diabetes that is driving prevalence of diabetic neuropathy, advancement in early diagnosis as well as launch of the promising therapies which will positively impact DPN market.

DelveInsight added a new report titled "Diabetic Peripheral Neuropathy MarketInsights, Epidemiology, and Market Forecast-2030" to its portfolio.

Key Highlights from Diabetic Peripheral Neuropathy Market report are:

Request for sample pages to know more onDiabetic Peripheral Neuropathy Epidemiology and Market Forecast

Diabetic Peripheral Neuropathy is a painful condition that is caused by nerve damage from diabetes. It is a common prevalent complication in neurological damage of Type 1 and Type 2 diabetes.

There is a huge patient population pool affected by the disease; the Diabetic Peripheral Neuropathy market report covers the disease epidemiology that is segmented into Total Diagnosed Prevalent Cases of DPN, Total Prevalent Cases of Painful DPN and Gender-specific Prevalent cases of DPN in the 7MM from 2017 to 2030.

The total Painful Diabetic Peripheral Neuropathy Prevalent Cases were 3,857,945 in the United States in 2020. Also, females are more affected by the disease as compared to males for Diabetic Peripheral NeuropathyPrevalent in the US in 2020.

Click here to know more onDiabetic Peripheral Neuropathypipeline

Among the 7MM, the US accounts for 58% of the overall market size of DPN. Among the EU-5 countries, Germany accounts for the highest market size for DPN. Diabetic Peripheral Neuropathy market has a diverse pipeline with several promising therapies. Also, Gene therapy has been developed for DPN pain management. Of the emerging therapies, the most anticipated product to get launched is VM202 Apart from this, other products include VM202 (Helixmith), NYX-2925 (Aptinyx), WST-057 (4% pirenzepine) (WinSanTor, Inc.), Ricolinostat (Regenacy Pharmacuticals), NRD.E1 (Novaremed Ltd.), Cebranopadol (Grnenthal GmbH), GRC 17356 (Glenmark Pharmaceuticals), and others are also expected to enter the market by 2030 as effective therapies. The potential launch of these emerging drugs will aid in overall market growth. There are a couple of market drivers which will be driving the market. One such factor will be an early diagnosis of the DPN because of the advancements happening in the DPN diagnostic approaches. As the patient pool for diabetic peripheral neuropathy is quite large, and there is no treatment for reversal of disease, this indication withholds a plethora of opportunities for drug development companies. No doubt that the clinical pipeline contains a large number of drugs; however, previously multiple clinical trial failures gave a setback and limited the research and development in the DPN domain. So far it has been clear that path traversed is not easy in DPN research as the long-term clinical trials and low success rate in meeting the clinical endpoints may become threats for the investors to fund further.

There aremany key players robustly involved in developing potential drugs and they are a ray of hopefor DPN patients such as:1. VM2022. NYX-29253. WST-0574. Ricolinostat5. ISC 175366. NRD135S.E17. Cebranopadol8. GRC 173569. MEDI735210. Trazodone/GabapentinAnd many others

The key players involved in Diabetic Peripheral Neuropathy market are:1. Helixmith2. Aptinyx3. WinSanTor, Inc4. Regenacy Pharmacuticals5. Ichnos Science6. Novaremed7. Grnenthal GmbH8. Glenmark Pharmaceuticals9. AstraZeneca10. AngeliniAnd many others

The reasons for buying Diabetic Peripheral Neuropathy market report:

Table of contents

1. Key Insights

2. Executive summary

3. Diabetic Peripheral Neuropathy Market Overview at a Glance

4. Diabetic Peripheral Neuropathy Epidemiology and Market Methodology

5. Diabetic Peripheral Neuropathy Disease Background and Overview

6. Diabetic Peripheral Neuropathy Epidemiology and Patient Population

6.1. Key Findings

6.2. Total Diagnosed Prevalent cases of Diabetic Peripheral Neuropathy in 7MM

6.3. United States

6.4. EU5

6.5. Germany

6.6. France

6.7. Italy

6.8. Spain

6.9. United Kingdom

6.10. Japan

7. Diabetic Peripheral Neuropathy Treatment and Management

8. Diabetic Peripheral Neuropathy Unmet need

9. Diabetic Peripheral Neuropathy Marketed Drugs

9.1. Key cross competition

9.2. Qutenza: Grnenthal

9.3. Tarlige: Daiichi Sankyo

10. Diabetic Peripheral Neuropathy Emerging drugs

10.1. Key cross competition

10.2. VM202: Helixmith

10.3. NYX-2925: Aptinyx

10.4. WST-057: WinSanTor

10.5. Ricolinostat: Regenacy Pharmaceuticals

10.6. Cebranopadol: Grnenthal

10.7. ISC 17536: Ichnos Science

10.8. NRD135S.E1: Novaremed

10.9. MEDI7352: AstraZeneca

10.10. Trazodone/Gabapentin: Angelini

11. Diabetic Peripheral Neuropathy Market Size

11.1. Key Findings

11.2. Total Market Size of Painful Diabetic Peripheral Neuropathy in 7MM

11.3. Diabetic Peripheral Neuropathy Market Outlook: 7 MM

11.4. United States

11.5. EU5

11.6. Germany

11.7. France

11.8. Italy

11.9. Spain

11.10. United Kingdom

11.11. Japan

12. Diabetic Peripheral Neuropathy Reimbursement policies

13. Market Drivers

14. Market Barriers

15. SWOT Analysis

16. KOL Views

17. Diabetic Peripheral Neuropathy Case Report

18. A Case Report of Diabetic Peripheral Neuropathy

19. Bibliography

20. Appendix

21. Diabetic Peripheral Neuropathy Report Methodology

22. DelveInsight Capabilities

23. Disclaimer

24. About DelveInsight

Request a WebEx Demo to get a walk-through of the Diabetic Peripheral Neuropathy Market Report:

Related Reports:

Diabetic Peripheral Neuropathy Epidemiology Forecast-2030 report delivers an in-depth understanding of the disease, historical, forecasted epidemiology trends of DPN in the 7 MM.

Diabetic Peripheral Neuropathy Pipeline Insight, 2020 report by DelveInsight outlays comprehensive insights of present clinical development scenario and growth prospects across the Diabetic Peripheral Neuropathy market.

About DelveInsight

DelveInsight is a premier Business Consulting and Market Research firm, focused exclusively on the life science segment. With a wide array of smart end-to-end solutions, the firm helps the global Pharmaceutical, Bio-Tech and Medical devices companies formulate prudent business decisions for improving their performances to stay ahead of the competitors.

Contact us:



Continued here:
Diabetic Peripheral Neuropathy Market is Expected to Increase with a CAGR of 12% for the Study Period of 2017-2030: DelveInsight - P&T Community

Recommendation and review posted by Bethany Smith

Concise Report 2020: Gene Therapy Market Competitive Landscape and Industrial Growth| The Impact of COVID-19 Disruption During 2029 – News Distinct

Worldwide Gene Therapy Market, [Forecast 2020-2029] Succinct Study Report is in-depth survey on the current state of the global Gene Therapy industry with focus on short term and long term impact analysis of COVID-19/CORONAVIRUS. The report provides key statistics on the market status of the Gene Therapy manufacturers and is a valuable source of guidance and direction for companies and individuals interested in the industry.

The Gene Therapy Market report covers detailed competitive outlook including the market share and company profiles of the key participants operating in the global market. Vital key players profiled in the report include Novartis, Kite Pharma Inc, GlaxoSmithKline PLC, Spark Therapeutics Inc, Bluebird bio Inc, Genethon, Transgene SA, Applied Genetic Technologies Corporation, Oxford BioMedica PLC, NewLink Genetics Corp., Amgen Inc. Company profile includes assign such as company summary, SWOT analysis and current developments, financial summary, product specifications, production value, business strategy and planning. This report analyzes the top players in global market, and splits the Gene Therapy market by vector type, gene type, application, and region.

|| Access insightful study with over 100+ pages, list of tables & figures, profiling 10+ companies. Ask for Free Sample Copy(PDF) @

Through the statistical analysis, the report depicts the global total market of the Gene Therapy industry including capacity, production value, cost/profit, supply/demand, production and import/export. The total market is further divided by company, by country, and by application/type for the competitive landscape analysis. The report then estimates the 2020-2029 market development trends of the Gene Therapy industry. Analysis of upstream raw materials, downstream demand and current market dynamics is also carried out in this report.

In the end, the report makes some important proposals for a new project of the Gene Therapy Industry before evaluating its feasibility. Overall, the report provides an in-depth insight into the 2020-2029 global Gene Therapy industry covering all important parameters.

The Final Report will cover the impact analysis of COVID-19 on this industry (Global and Regional Market).

>>>>Download Here- Short Term & Long Term Impact Analysis of Gene Therapy Market<<<<

Promising Regions & Countries Mentioned In The Gene Therapy Market Report:

North America (U.S. & Canada)

Latin America (Brazil, Mexico, Argentina, Rest of Latin America)

Europe (U.K., Germany, France, Italy, Spain, Hungary, Belgium, Netherlands & Luxembourg, NORDIC, Poland, Turkey, Russia, Rest of Europe)

Asia-Pacific (China, India, Japan, South Korea, Indonesia, Malaysia, Australia, New Zealand, Rest of Asia-Pacific)

The Middle East and Africa (Israel, GCC [Saudi Arabia, UAE, Bahrain, Kuwait, Qatar, Oman], North Africa, South Africa, Rest of The Middle East and Africa)

Years Considered For This Report:

Historical Years :2013-2018

Base Year :2019

Estimated Year :2020

Forecast Period: 2020-2029

A complete value chain of the global Gene Therapy Market is presented in the research report. It is associated with the review of the downstream and upstream components of the Gene Therapy Market. The market is bifurcated on the basis of the categories of products and the customer application segments. The market analysis demonstrates the expansion of each segment of the global Gene Therapy Market. The research report assists the user in taking a decisive step that will be a milestone in developing and expanding their businesses in the global Gene Therapy Market.

For any special requirements about this report[Click Here- For Enquiry & Report Customization]please let us know and we can provide custom reports.

Key Answers Captured in Report?

Which geography would have better demand for products/services?

What are the strategies adopted by big players in the regional market?

Which country would see the steep rise in CAGR & year-on-year (Y-O-Y) growth?

What is the current & expected market size in the next five years?

What is the market feasibility for long term investment?

What opportunity the country would offer for existing and new players in the market?

What is the risk involved for suppliers in the geography?

What factors would drive the demand for the product/service in the near future?

What is the impact analysis of various factors in market growth?

There Are 13 Chapters To Thoroughly Display The Gene Therapy Market:

Chapter 1:Global Gene Therapy Market Overview, Product Overview, Market Segmentation, Market Overview of Regions, Market Dynamics, Limitations, Opportunities and Industry News and Policies.

Chapter 2:Global Gene Therapy Market Chain Analysis, Upstream Raw Material Suppliers, Major Players, Production Process Analysis, Cost Analysis, Market Channels and Major Downstream Buyers.

Chapter 3:Value Analysis, Production, Growth Rate and Price Analysis by Type of Gene Therapy.

Chapter 4:Downstream Characteristics, Consumption and Market Share by Application of Gene Therapy.

Chapter 5:Production Volume, Price, Gross Margin, and Revenue ($) of Gene Therapy by Regions (2013-2020).

Chapter 6:Gene Therapy Production, Consumption, Export and Import by Regions (2013-2020).

Chapter 7:Gene Therapy Market Status and SWOT Analysis by Regions.

Chapter 8:Global Competitive Landscape, Product Introduction, Company Profiles, Market Distribution Status by Players of Gene Therapy.

Chapter 9:Gene Therapy Market Analysis and Forecast by Type and Application (2020-2029).

Chapter 10:Global Market Analysis and Forecast by Regions (2020-2029).

Chapter 11:Global Industry Characteristics, Key Factors, New Entrants SWOT Analysis, Investment Feasibility Analysis.

Chapter 12:Market Conclusion of the Whole Report.

Chapter 13:Appendix Such as Methodology and Data Resources of This Research

....For Detailed InformationClick Here For Complete TOC

Why MarketResearch.Biz?

Robust research methodology of Gene Therapy market

Technically renowned study with overall Gene Therapy industry know-how

Focus on Gene Therapy drivers, restraints, opportunities, and threats till 2029

Based on complete research, we offer the clear view of real Gene Therapy market scenario and help clients with making an important business judgment

Read more:
Concise Report 2020: Gene Therapy Market Competitive Landscape and Industrial Growth| The Impact of COVID-19 Disruption During 2029 - News Distinct

Recommendation and review posted by Bethany Smith

Global Gene Therapy Market Size to Expand Significantly by the End of 2025 – Cole of Duty

The report titledGlobalGene TherapyMarketpresents a much-awaited study on the global market which summarizes the market in terms of definitions, applications, types, and leading key players/manufacturers ofGene Therapyindustry. The report comprises insights related to the present scenario of the market and the industry scenario over the forecast time-span from 2020 to 2025. The report reveals a comprehensive study on market dynamics including drivers, restraints and opportunities, recent trends, and industry performance analysis, and detailed value chain assessment. It features global and regional data and over top key players profiles, this report gives the guide to exploring opportunities in theGene Therapyindustry. The report is partitioned based on driving players, applications, and regions.

NOTE: This report takes into account the current and future impacts of COVID-19 on this industry and offers you an in-depth analysis of GlobalGene TherapyMarket.


About The Industry:

The previous, current market situation, and prospects of the market are examined. The comprehensive competitive analysis section includes detailed profiling of leading manufacturers operating in the global market. Highlights of the segmentation study covered in this report include price, revenue, sales, sales growth rate, and market share by product. It enfolds insightful analysis of competition intensity, segments, environment, and product innovations to provide deep comprehension of the completeGene Therapymarket environment. An extensive analysis of market-changing market trends, driving factors, growth potentials, investment opportunities, threats, and restraints has been given in the report.

Top companies profiled in this report include:Spark Therapeutics LLC, Bluebird Bio, UniQure N.V., Juno Therapeutics, GlaxoSmithKline, Chiesi Farmaceutici S.p.A., Bristol Myers Squibb, Celgene Corporation, Human Stem Cell Institute, Voyager Therapeutics, Shire Plc, Sangamo Biosciences, Dimension Therapeutics and others.

The report is a professional and comprehensive research report on the worlds major regional market conditions, focusing on the main regions:North America, Europe, Asia Pacific, South America, and the Middle East and Africa.

Moreover, the report is presented in an efficient way that involves basic terminology, a basic outline, agreements, and certain facts as per comprehension. Clients needs ensure a thorough understanding of market capacities. It provides market-driven results deriving feasibility studies for client needs. The report presents an overview of key marketing strategies and key sales channels adopted in the globalGene Therapymarket.


Analysis of Key Aspects Covered In TheGene TherapyMarket Report:

Industry Scenario: Definitions, classifications, applications, and globalGene Therapymarket overview; product specifications; manufacturing processes; cost structures, raw materials

Key Market Dynamics: The report includes production strategies and methodologies, development platforms, and the product model. The latest market trends, development outlines, and research methodologies are provided for the projected period.

Competitive Landscape: The competitive analysis involves the market share of major players, along with the new projects and strategies adopted by players in the past five years. Comprehensive company profiles cover the product

Customization of the Report:This report can be customized to meet the clients requirements. Please connect with our sales team ([emailprotected]), who will ensure that you get a report that suits your needs.

See the rest here:
Global Gene Therapy Market Size to Expand Significantly by the End of 2025 - Cole of Duty

Recommendation and review posted by Bethany Smith

InveniAI Announces Strategic Partnership with TB Alliance to Advance the Development of Transformative Therapies for Tuberculosis – GlobeNewswire

GUILDFORD, Conn., June 02, 2020 (GLOBE NEWSWIRE) -- InveniAI LLC, a global leader pioneering the application of artificial intelligence (AI) and machine learning (ML) to transform innovation across drug discovery and development, is pleased to announce a strategic partnership with TB Alliance, a non-profit organization dedicated to the discovery, development, and delivery of better, faster-acting and affordable tuberculosis (TB) drugs. TB Alliance will make use of InveniAIs AI and machine learning platform, AlphaMeld, to identify and accelerate transformative therapies for the management, treatment, and cure of TB, which remains the worlds top infectious disease killer.

TB is an infectious respiratory disease that seriously endangers health. Approximately one-quarter of the world's population is estimated to be infected with latent TB, of which 13 million are living in the United States. Globally, about 10 million people develop active TB each year and 1.5 million die from their disease. TB bacteria are becoming increasingly resistant to conventional six-month antibiotic treatments, with an estimated 500,000 people developing drug-resistant forms of TB each year.

Our mission is to develop and deliver new TB treatments that address the significant unmet needs that TB patients face today, said Nader Fotouhi, Ph.D., Chief Scientific Officer, TB Alliance. There has been growing interest in developing novel immunotherapeutic strategies that address drug-resistant TB as well as shorten the length of treatments, which can impose a significant burden on patients. Stimulating the immune system to help the body fight disease may provide a unique strategy to effectively treat patients with TB and drug-resistant TB. We are excited to deploy AI-powered technology as we strive to reshape the TB treatment landscape.

Immunomodulatory approaches have proven successful for treating many infectious diseases and have gained momentum for those diseases with an immune component such as oncology, neuro-inflammation, and immuno-metabolism, among others. There are several pathways, targets, and drugs that represent a fertile ground to apply AI and ML to create novel concepts efficiently, rapidly, and at scale. This important collaboration with the TB Alliance comes at an opportune time coinciding with significant success in the clinical development of assets delivered by AlphaMeld, said InveniAIs President and CEO, Krishnan Nandabalan, Ph.D.

About TB Alliance TB Alliance is a not-for-profit organization dedicated to finding faster-acting and affordable drug regimens to fight TB. Through innovative science and with partners around the globe, we aim to ensure equitable access to faster, better TB cures that will advance global health and prosperity. TB Alliance operates with support from Australias Department of Foreign Affairs and Trade, Bill & Melinda Gates Foundation, Cystic Fibrosis Foundation, European & Developing Countries Clinical Trials Partnership, Germanys Federal Ministry of Education and Research through KfW, Global Health Innovative Technology Fund, Indonesia Health Fund, Irish Aid, Medical Research Council (United Kingdom), National Institute of Allergy and Infectious Disease, Netherlands Ministry of Foreign Affairs, Rockefeller Foundation, United Kingdom Department for International Development, and the United States Agency for International Development. For more information, visit

About AlphaMeld AlphaMeld is an AI-based platform powered with machine learning algorithms. The platform accelerates innovation by identifying alpha signals for targets, drugs, and healthcare products and technologies. Primed with data sets that have been cleaned curated and connected for over a decade the platform generates testable hypotheses based on an ideal mode of pharmacotherapy (antibody, protein replacement, siRNA, mRNA, small molecule, cell and gene therapy, and gene-editing modalities), disease severity, gene ontology, disease pathways, proteinopathies, standard of care, emerging innovation, and enabling technologies while factoring in medical, scientific, strategic, and commercial considerations. AlphaMeld operates in real-time and in a rapidly changing and diverse data environment.

About InveniAIInveniAI LLC, based in Guilford, Conn., is a global leader pioneering the application of artificial intelligence (AI) and machine learning (ML) to transform innovation across drug discovery and development by identifying and accelerating transformative therapies for diseases with unmet medical needs. The company leverages AI and ML to harness petabytes of disparate data sets to recognize and unlock value for AI-based drug discovery and development. Numerous industry collaborations in Big Pharma, Specialty Pharma, Biotech, and Consumer Healthcare showcase the value of leveraging our technology to meld human experience and expertise with the power of machines to augment R&D decision-making across all major therapeutic areas. The company leverages the AlphaMeld platform to generate drug candidates for our industry partners and internal drug portfolio. For more information, visit

Contact:Anita Ganjoo, Ph.D.CommunicationsInveniAIT: +1

Thomas LynchCommunicationsTB AllianceT: +1

Original post:
InveniAI Announces Strategic Partnership with TB Alliance to Advance the Development of Transformative Therapies for Tuberculosis - GlobeNewswire

Recommendation and review posted by Bethany Smith

Gene Therapy Market Research Report 2020: Key Players, Applications, Drivers, Trends and Forecast to 2026 – WaterCloud News


In addition, the report categorizes product type and end uses as dynamic market segments that directly impact the growth potential and roadmap of the target market. The report highlights the core developments that are common to all regional hubs and their subsequent impact on the holistic growth path of the Gene Therapy market worldwide. Other valuable aspects of the report are the market development history, various marketing channels, supplier analysis, potential buyers and the analysis of the markets industrial chain.

Ask For Discounts @

Table of Content

1 Introduction of Gene Therapy Market

1.1 Overview of the Market1.2 Scope of Report1.3 Assumptions

2 Executive Summary

3 Research Methodology of Verified Market Research

3.1 Data Mining3.2 Validation3.3 Primary Interviews3.4 List of Data Sources

4 Gene Therapy Market Outlook

4.1 Overview4.2 Market Dynamics4.2.1 Drivers4.2.2 Restraints4.2.3 Opportunities4.3 Porters Five Force Model4.4 Value Chain Analysis

5 Gene Therapy Market, By Deployment Model

5.1 Overview

6 Gene Therapy Market, By Solution

6.1 Overview

7 Gene Therapy Market, By Vertical

7.1 Overview

8 Gene Therapy Market, By Geography

8.1 Overview8.2 North America8.2.1 U.S.8.2.2 Canada8.2.3 Mexico8.3 Europe8.3.1 Germany8.3.2 U.K.8.3.3 France8.3.4 Rest of Europe8.4 Asia Pacific8.4.1 China8.4.2 Japan8.4.3 India8.4.4 Rest of Asia Pacific8.5 Rest of the World8.5.1 Latin America8.5.2 Middle East

9 Gene Therapy Market Competitive Landscape

9.1 Overview9.2 Company Market Ranking9.3 Key Development Strategies

10 Company Profiles

10.1.1 Overview10.1.2 Financial Performance10.1.3 Product Outlook10.1.4 Key Developments

11 Appendix

11.1 Related Research

Customized Research Report Using Corporate Email Id @

About Us:

Market Research Intellect provides syndicated and customized research reports to clients from various industries and organizations with the aim of delivering functional expertise. We provide reports for all industries including Energy, Technology, Manufacturing and Construction, Chemicals and Materials, Food and Beverage and more. These reports deliver an in-depth study of the market with industry analysis, market value for regions and countries and trends that are pertinent to the industry.

Contact Us:

Mr. Steven Fernandes

Market Research Intellect

New Jersey ( USA )

Tel: +1-650-781-4080

Tags: Gene Therapy Market Size, Gene Therapy Market Trends, Gene Therapy Market Growth, Gene Therapy Market Forecast, Gene Therapy Market Analysis Sarkari result, Government Jobs, Sarkari naukri, NMK, Majhi Naukri,

Go here to read the rest:
Gene Therapy Market Research Report 2020: Key Players, Applications, Drivers, Trends and Forecast to 2026 - WaterCloud News

Recommendation and review posted by Bethany Smith

Cell And Gene Therapy Consumables Market Size, Share And Top Key Players During 2020-2027 – WaterCloud News

The report covers the forecast and analysis of the Cell and Gene Therapy Consumables market on a global and regional level. The study provides historical data from 2015 to 2018 along with a forecast from 2020 to 2027 based on revenue (USD Million). The study includes drivers and restraints of the Cell and Gene Therapy Consumables market along with the impact they have on the demand over the forecast period. Additionally, the report includes the study of opportunities available in the Cell and Gene Therapy Consumables market on a global level.

Download Sample of This Strategic Report:

In order to give the users of this report a comprehensive view of the Cell and Gene Therapy Consumables market, we have included a competitive landscape and an analysis of Porters Five Forces model for the market. The study encompasses a market attractiveness analysis, wherein all the segments are bench marked based on their market size, growth rate, and general attractiveness.

The report provides company market share analysis to give a broader overview of the key players in the market. In addition, the report also covers key strategic developments of the market including acquisitions & mergers, new service & product launches, agreements, partnerships, collaborations & joint ventures, research & development, and regional expansion of major participants involved in the market on a global and regional basis.

The study provides a decisive view of the Cell and Gene Therapy Consumables market by segmenting the market based on product type, application/therapeutics, and regions. All the segments have been analyzed based on present and future trends and the market is estimated from 2019 to 2027. The regional segmentation includes the current and forecast demand for North America, Europe, Asia Pacific, Latin America, and the Middle East and Africa.

A rise in the awareness about the gene & cell therapies will propel the market growth during the period from 2020 to 2027. Nevertheless, conducting randomized control tests will inhibit the expansion of the market during the forecast timeline. However, the growing trend for treating neurodegenerative ailments through the use of gene treatment will proliferate the market growth over the forecast period.

The expansion of the market during the forecast timespan is owing to the high frequency of chronic ailments including cancer and heart disorders. Apart from this, inflation in the occurrence of these disorders produces lucrative demand for enhanced therapies and this will culminate in the market demand over the forecast time span.

Request For Full Report:

Based on the product type, the market is sectored into Kits & Buffers, Diagnostic Assay, Culture Medium, and Cryopreservation Media. Application/ Therapeutics- wise, the market for cell and gene therapy consumables are classified into Cardiovascular, Urology, Dermatology, Critical Care, Respiratory, Endocrine & Metabolic, Neuroscience, Hematology & Oncology, Obstetrics, Immunology, and Gastroenterology.

Some of the key players in the market include Amgen Inc., ATLANTA BIOLOGICALS, bluebird bio, Inc., Cook, Dendreon Pharmaceuticals, LLC, Fibrocell Science, Inc., General Electric, Kolon TissueGene, Inc., Orchard Therapeutics plc., Pfizer, Inc., PromoCell GmbH, RENOVA THERAPEUTICS, Sibiono GeneTech Co. Ltd., Spark Therapeutics, Inc., Vericel, Helixmith Co., Ltd., and Vitrolife.

About Kenneth Research

Kenneth Research is a reselling agency providing market research solutions in different verticals such as Automotive and Transportation, Chemicals and Materials, Healthcare, Food & Beverage and Consumer Packaged Goods, Semiconductors, Electronics & ICT, Packaging, and Others. Our portfolio includes set of market research insights such as market sizing and market forecasting, market share analysis and key positioning of the players (manufacturers, deals and distributors, etc), understanding the competitive landscape and their business at a ground level and many more. Our research experts deliver the offerings efficiently and effectively within a stipulated time. The market study provided by Kenneth Research helps the Industry veterans/investors to think and to act wisely in their overall strategy formulation

Contact Us

Kenneth Research

Email : [emailprotected]

Phone: +1 313 462 0609

Here is the original post:
Cell And Gene Therapy Consumables Market Size, Share And Top Key Players During 2020-2027 - WaterCloud News

Recommendation and review posted by Bethany Smith

Biopreservation Market Analysis 2020 by Technologies, Production, Rising Demand, Industry Share, End-User and Company Profiling till 2025 – Cole of…

This intensive research presentation on the given Biopreservation market is well crafted by various research experts with ample investments in both primary and secondary research methodologies, to specifically incur substantial information on the discussed Biopreservation market forecasts that tangibly have a lingering influence on strategic business discretion and investment planning.

Top Leading Key Players are:

LabVantage Solutions, Thermo-Fischer Scientific, Custom Biogenic Systems, Biomatrica, Qiagen and more.

Get Sample PDF (including COVID19 Impact Analysis, full TOC, Tables and Figures) of Biopreservation Market @

The report also sheds decisive light on other core aspects such as sales channel management, distribution network, cost valuation and consumer preferences. This intensive research presentation on Biopreservation market through this analytical survey on is poised to offer report readers with ample competitive edge to fabricate revenue specific market decisions. This report on the discussed Biopreservation market also sheds critical understanding on the historical growth trail, mediated by several market components that collectively influenced the uncompromised growth trail. Report analysts and research experts in have vividly documented a thorough analytical review of market beginning with appropriate details about market definition, overview, opportunity assessment and the like, later succeeding with decisive understanding on market segmentation encompassing primarily on all the growth propellants in the Biopreservation market.

Decisive input on competition intelligence, internationally acknowledged analytical tools such as SWOT analysis, PESTEL analysis as well PORTERs Five Point analysis have all been critically analyzed in this decisive report to logically decipher competition intensity, opportunity assessment as well as barrier analysis, duly brainstormed by market analysts in their comprehensive report on the Biopreservation market.

Browse the complete report Along with TOC @

Global Biopreservation market is segmented based by type, application and region.

Based on Type, the market has been segmented into:

By Cell Provider Outlook, market is segmented into:

Tumor cellshESCiPSCMSCCD19+CD34+Others

Based on application, the market has been segmented into:

By Application, market is segmented into:

Drug discoveryBio-bankingVeterinary IVFHuman spermHuman eggsRegenerative medicineGene therapyCell therapyOthersBy Product Outlook, market is segmented into:

Laboratory information management systemMediaEquipment.

The report highlights various factors and reasons that collectively influence the psyche of market participants and stakeholders and their collective comprehension about the need and requirement of Biopreservation market offerings available indiscretion for a wide variety of services and solutions that have a tangible and durable impact on consumer buying preferences and eventual buying behavior.

A birds eye view analytical approach has been primary to gauge decisive market trends in the discussed Biopreservation market, citing specific input on essential factors such as overall household income and the core factors that mediate reliance on the aforementioned Biopreservation market. This contemporary research presentation and detailed market research synopsis on the Biopreservation market is a real time presentation of all the specific market developments that have a lingering impact on current growth trajectory, besides also harping on vital predictions in the realm of future growth scope.

For Any Query on the Biopreservation Market:

About Us :

Adroit Market Research is an India-based business analytics and consulting company. Our target audience is a wide range of corporations, manufacturing companies, product/technology development institutions and industry associations that require understanding of a markets size, key trends, participants and future outlook of an industry. We intend to become our clients knowledge partner and provide them with valuable market insights to help create opportunities that increase their revenues. We follow a code Explore, Learn and Transform. At our core, we are curious people who love to identify and understand industry patterns, create an insightful study around our findings and churn out money-making roadmaps.

Contact Us :

Ryan JohnsonAccount Manager Global3131 McKinney Ave Ste 600, Dallas,TX 75204, U.S.APhone No.: USA: +1 972-362 -8199 / +91 9665341414

See the original post here:
Biopreservation Market Analysis 2020 by Technologies, Production, Rising Demand, Industry Share, End-User and Company Profiling till 2025 - Cole of...

Recommendation and review posted by Bethany Smith

A new Benchmark in shrimp production – The Fish Site

As Benchmarks shrimp facility in Florida begins to gear up towards commercial production, Oscar Hennig, operations director of Benchmark Genetics shrimp-breeding programme who has been in the shrimp sector for nearly 30 years explains to The Fish Site what he hopes to achieve.

Benchmark Genetics

Ive been involved in the sector since 1991, starting off on farms in Australia. After finishing my masters in aquaculture in Florianpolis [in southern Brazil] I received a scholarship from the government of Japan for a two-year research project with shrimp immunology at the Shimonoseki National Fisheries University. From there I returned to Brazil for two years running a diagnostics lab for shrimp at the LABOMAR research institute. In the meantime, to make ends meet, I leased a growout farm. P. vannamei [whiteleg shrimp] farming was just starting in north-east Brazil and there was the need for expertise to help the transition from P. subtilis [southern brown shrimp].

At the end of 1999 I moved permanently to Hawaii, to manage a satellite facility of the Oceanic Institute, in Kona. I have been in Kona ever since, working as breeding-programme manager for different companies, with P. monodon [giant tiger prawn], P. stylirostris [blue shrimp] and mainly P. vannamei.

At the end of 2016 I was hired as a director for Benchmark Genetics, after Benchmark had bought CENIACUA, a P. vannamei breeding programme in Colombia. My role has been to bring this to the international arena.

Oscar Hennig

I was impressed by the CENIACUA facility, and the crew running it, in Cartagena we had as much space as we wanted and as many people as we needed, as the jobs were in the local community.

However, Cartagena doesnt have great logistics and we realised that we need a base in the US to improve our ability to export our stocks.

[The Central Florida town of] Fellsmere was suitable for a number of reasons, not least for being close to three international airports. It is also 30km from the coast, which helps with our biosecurity and also to protect us from the hurricanes that can devastate the Florida coast.

Back in 2017, when we selected the site, my only concern was that we were sourcing water from a well this can impact the fertilisation ratio but weve managed to produce steady numbers of nauplii.

Benchmark Genetics

The water comes from 750m deep, and the well brings a sterile (zero dissolved oxygen), ~32 ppt saline water that is second to none. Due to the inland location, discharging water is a challenge, so all our systems work on recirculation or on biofloc.

All activities are conducted indoors from maturation, to algae, to grow-out, to packing so the biosecurity is excellent.

Im proud of how its turned out and Im really happy with the team weve created. There are currently 15 people involved and theres plenty of space to expand. At the moment were operating at about one fifth of our capacity, as were conducting presale trials, in order to fine tune the lines of shrimp that are needed in our main markets China, Vietnam, Indonesia and Thailand and these are now being tested in a commercial environment.

Most shrimp producers only offer one product but there are so many production systems used by the global shrimp industry and we saw that one size does not fit all. As a result, we decided to cater for a range of options and have launched three lines commercially.

The first, which weve been developing since 2008, is resistant to whitespot, EMS and other diseases. Called BMK Protect this is mainly for customers in northern China, and other areas facing disease challenges. It shows its true potential in harsh/disease conditions.

The second line was bred specifically to improve performance in sites with low salinity: shrimp farming is becoming increasingly popular in water thats less than 5 ppt. It now accounts for roughly 60 percent of Indian shrimp production, 50 percent in China, 15 percent in Vietnam and 15 to 20 percent in Thailand.

The third line, called BMK Yield, balances growth rates with survival to ensure steady production. It produces a consistent yield and a high rate of survival, making it ideal for farms that are working with processing plants, as it allows the farmer to provide a steady supply of raw material.

Benchmark Genetics

At this moment we are using some of that capacity to produce PLs for farmers, in the US and abroad. The PPL will go to our partners multiplication centres worldwide. China has been the main market during this presale year, and BMK Protect has been the number one line. The other two are doing well in the presale, but their evaluation still ongoing.

Breeding without ablation is not a big deal for us; it takes more planning and a few adjustments but nothing major. It is not done at the commercial hatcheries [as opposed to broodstock production facilities] due to a ~30 percent reduction in nauplii production. This reduction off nauplii output is mainly due to the lower frequency of female spawning, not due to lower levels of nauplii per spawn.

We believe that PL produced by non-ablated females are stronger. We ran some trials to support this belief and found that the eggs were bigger in non-ablated females, which makes sense as they have more time to go through the maturation process. We have other trials in mind that we will pursue once we get back to a normal routine.

Consolidation of the industry at different levels and partnership with local companies. I see the industry moving in two extreme directions: high-density, enclosed, biosecure farming systems and extensive open ponds, with not much left in the middle.

There was a small decline in sales during February and it has been hard to get cargo space and to predict when flights would go logistics have been crazy and transport prices also increased. However, I am optimistic that, once Covid-19 is a thing of the past, people will be wanting to celebrate life and demand for shrimp will increase beyond levels prior to this pandemic. As a result, our plan to expand is still in place.

The rest is here:
A new Benchmark in shrimp production - The Fish Site

Recommendation and review posted by Bethany Smith